<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id><journal-title-group><journal-title>NPJ Parkinson's Disease</journal-title></journal-title-group><issn pub-type="epub">2373-8057</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7935902</article-id><article-id pub-id-type="publisher-id">161</article-id><article-id pub-id-type="doi">10.1038/s41531-021-00161-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Dynamic control of the dopamine transporter in neurotransmission and homeostasis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3045-652X</contrib-id><name><surname>Bu</surname><given-names>Mengfei</given-names></name><address><email>mbu@ufl.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Farrer</surname><given-names>Matthew J.</given-names></name><address><email>m.farrer@ufl.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1533-8771</contrib-id><name><surname>Khoshbouei</surname><given-names>Habibeh</given-names></name><address><email>habibeh@ufl.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.15276.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8091</institution-id><institution>Department of Neurology and Fixel Institute, </institution><institution>University of Florida, </institution></institution-wrap>Gainesville, FL USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.15276.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8091</institution-id><institution>Department of Neuroscience, </institution><institution>University of Florida, </institution></institution-wrap>Gainesville, FL USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>7</volume><elocation-id>22</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>8</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The dopamine transporter (DAT) transports extracellular dopamine into the intracellular space contributing to the regulation of dopamine neurotransmission. A reduction of DAT density is implicated in Parkinson&#x02019;s disease (PD) by neuroimaging; dopamine turnover is dopamine turnover is elevated in early symptomatic PD and in presymptomatic individuals with monogenic mutations causal for parkinsonism. As an integral plasma membrane protein, DAT surface expression is dynamically regulated through endocytic trafficking, enabling flexible control of dopamine signaling in time and space, which in turn critically modulates movement, motivation and learning behavior. Yet the cellular machinery and functional implications of DAT trafficking remain enigmatic. In this review we summarize mechanisms governing DAT trafficking under normal physiological conditions and discuss how PD-linked mutations may disturb DAT homeostasis. We highlight the complexity of DAT trafficking and reveal DAT dysregulation as a common theme in genetic models of parkinsonism.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Parkinson's disease</kwd><kwd>Transporters in the nervous system</kwd></kwd-group><funding-group><award-group><funding-source><institution>Funded by the Norman Fixel Institute for Neurological Diseases.</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>NIH: National Institute of Health, United States DA026947, NS071122, DA026947S1, DA043895</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><sec id="Sec2"><title>DAT, a regulator of dopamine neurotransmission and homeostasis</title><p id="Par2">Parkinson&#x02019;s disease (PD) is the second most common neurodegenerative disease and is best known as a movement disorder. Motor symptoms correlate with the progressive loss of dopaminergic neurons in the <italic>substantia nigra</italic> and Lewy pathology. However, a relative preservation of dopamine synthesis and an increase in turnover is frequently observed in patients early in their symptom onset<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref></sup>. This supports the hypothesis that dysfunction in presynaptic dopamine neurotransmission may contribute to disease pathogenesis.</p><p id="Par3">Midbrain dopaminergic neurons have a very distinct morphology and mechanism of action. In the rat a single dopaminergic neuron in the <italic>substantia nigra</italic> is estimated to influence ~75,000 striatal neurons via as many as 370,000 axonal boutons, and in humans the organization may be four times as complex<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. Dopamine release can originate from varicosities without termination of the axons, from <italic>en passant</italic> synapses that are often perisynaptic and extrasynaptic. Hence dopamine signaling is not restricted to a single synaptic location but has a large sphere of influence, an architecture that leads to volume transmission<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. Extracellular dopamine critically modulates movement, motivation and learning by acting on its receptor. Different dopamine receptor subtypes display heterogeneity in their regional expression, substrate affinity and G-protein coupling dynamics<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Depending on the type of receptor activated, dopamine can have completely opposing effects on target neurons. Volume transmission and dopamine receptor heterogeneity both highlight the need to dynamically regulate extracellular dopamine in time and space - a function diligently executed by the dopamine transporter (DAT, SLC6A3).</p><p id="Par4">DAT is a plasma membrane protein selectively expressed in dopaminergic neurons and critically regulates dopamine neurotransmission<sup><xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref></sup>. As a member of SLC6 gene family of Na<sup>+</sup>/Cl<sup>-</sup> dependent neurotransmitter transporters, DAT couples the transport of Na<sup>+</sup> ions down the electrochemical gradient with the reuptake of extracellular dopamine into the intracellular space. Lowering the concentration of extracellular dopamine limits its duration of action and regulates dopamine transmission. Deletion of the DAT gene in mice greatly reduces tissue dopamine content, despite a great increase in the rate of dopamine synthesis<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, suggesting DAT reuptake is the primary mechanism for maintaining intracellular dopamine storage. Beyond simple reuptake of extracellular dopamine, DAT is capable of generating a depolarizing conductance that regulates the excitability of midbrain dopamine neurons both in vitro and in vivo<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Under certain conditions, DAT also mediates the release of intracellular dopamine via a reverse transport mechanism known as DAT-mediated dopamine efflux<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Recent studies have also identified DAT as a regulator of short-term plasticity in striatal dopamine release<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p></sec><sec id="Sec3"><title>DAT structure and modification</title><p id="Par5">DAT contains twelve transmembrane helices that harbor the primary substrate binding site and have large N- and C- terminals extended into the cytoplasm. DAT undergoes N-linked glycosylation on extracellular loop 2, which is important for surface targeting of the transporter. Pathogenic amino acid substitutions have been described near the Na<sup>+</sup> binding site that interfere with conformational changes during transport, resulting in dystonia-parkinsonism, and which highlight the functional significance of this transmembrane domain<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Additional rare substitutions have been implicated in attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD)<sup><xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup>. DAT N- and C- terminals have the most diverse structures among SLC6 family members, and these domains account for differential interaction profiles. Notably, the N-terminus of DAT harbors several secondary modification sites, including residues subject to phosphorylation<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and ubiquitination<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, that are important for the activity and trafficking of the transporter. The C-terminus contains domains for interactions with other proteins including &#x003b1;-synuclein<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, parkin<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, flotillin<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and protein kinase C (PKC)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Recently, RAS-like GTPase, Rit2 was shown to complex with DAT and regulate PKC-stimulated DAT trafficking<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Genetic variability in the Rit2 locus has been robustly associated with PD and several other dopaminergic disorders<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>.</p><p id="Par6">The high-resolution crystal structure of human DAT (hDAT) has not been solved as it is lipid associated and the protein aggregates during purification. Nevertheless, recent studies have resolved a partial structure of Drosophila melanogaster DAT (dDAT) in multiple conformational states. Hence, the functional dynamics of DAT and its interactions with ligands are being elucidated<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. At resting state, dDAT exists in an open and outward facing conformation. Upon substrate binding, an outward facing occluded conformation forms that is stabilized by salt bridges between key residues (the extracellular gate). Then the occluded complex transitions to become inward facing. Subsequent disruption of a separate set of salt bridges (the intracellular gate) allows substrate release into the intracellular space. Mutations that disrupt the conformational structure often lead to anomalous efflux or inefficient uptake activity<sup><xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup>. However, it should be noted that dDAT intracellular N- and C- termini were removed to facilitate crystallization. In addition, dDAT was crystallized as a monomer<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, whereas biochemical and microscopy data frequently detect dimers, oligomers and clusters of DAT molecules in DAT expressing model systems<sup><xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref></sup>. Oligomerization could influence DAT trafficking and surface expression. Small molecules, notably AIM100, may directly induce DAT oligomerization and subsequent endocytosis<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Readers are referred to the recent review for more detailed discussion on DAT oligomerization<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p></sec></sec><sec id="Sec4"><title>Regulation of DAT endocytosis</title><p id="Par7">Plasma membrane dopamine transporters are dynamically regulated by endocytic trafficking. Extensive studies have identified a variety of signaling pathways that lead to DAT internalization. The mechanisms of endocytic carrier formation and post-endocytic sorting of DAT largely depends on the signaling context. In this section, the mechanisms underlying DAT endocytosis are reviewed.</p><sec id="Sec5"><title>Clathrin-dependent Endocytosis</title><p id="Par8">Clathrin-mediated endocytosis (CME) was the first mechanism identified for DAT regulation and is best characterized by PKC activation<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>, which robustly drives the loss of surface DAT in heterologous systems and striatal tissues<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. New data suggests PKC activation may disrupt DAT interactions with Rit2, and with cytosolic nonreceptor tyrosine kinase (TNK2, formerly called activated p21CDC42 kinase; ACK1), that normally stabilize DAT in the plasma membrane<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. AIM-100 may also inhibit TNK2 and lower surface DAT<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. The effect of PKC can be arrested by blocking CME. For example, dynamin interacts with clathrin-coated pits and plays an important role in vesicle budding. Expression of dynamin p.K33E, a dominant-negative form of dynamin, or pharmacological inhibition of dynamin activity prevents phorbol 12-myristate 13-acetate (PMA)-induced loss of surface DAT in cell lines and <italic>ex-vivo</italic> striatal slices, respectively<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. Down regulation of clathrin heavy chain by siRNA or acute inhibition of clathrin function by pitstop2 prevents PMA-mediated DAT internalization in DAT expressing cell lines<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. However, dynamin is involved in both clathrin-dependent and clathrin-independent pathways including RhoA- and caveolar-mediated endocytosis<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Clathrin is also critically involved in a broad range of endocytic pathways including sorting of ubiquitinated proteins for lysosomal degradation<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Therefore, indirect regulation of clathrin and dynamin on PKC-mediated DAT internalization cannot be excluded. DAT complexes with Eps15, a component of clathrin-coated pits, in heterologous systems and midbrain neuronal cultures<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. However, immunogold-labeling has failed to observed DAT localization in clathrin-coated pits in the axonal terminals and soma of dopaminergic neurons<sup><xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref></sup>. Assessing DAT&#x02019;s interaction with clathrin and scaffold proteins, such as adaptor protein-2, in endogenously expressing systems may further clarify their role in DAT endocytosis.</p></sec><sec id="Sec6"><title>RhoA-mediated Clathrin-independent Endocytosis</title><p id="Par9">RhoA belongs to the Ras GTPase family and defines a clathrin-independent endocytic pathway<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. RhoA-mediated DAT endocytosis is most studied in the context of substrate exposure including amphetamine (AMPH); AMPH-induced DAT internalization was first described in HEK293 cells<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, and later confirmed in mid-brain neuronal cultures<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>, <italic>ex-vivo</italic> striatal and mid-brain slices<sup><xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>. AMPH-mediated DAT endocytosis is dynamin dependent<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, accompanied by the activation of RhoA and Rac1 in mouse mid-brain slices, and prevented by the inhibition of RhoA through PKA<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Similarly, dopamine treatment of rat mid-brain slices also increases RhoA activation and reduces surface DAT expression, and such effects are inhibited by pharmacological activation of the PKA-coupled D1 receptor<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. AMPH and dopamine-mediated DAT internalization is blocked by cocaine which occupies the substrate binding site of DAT and prevents transport activity<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>. Extracellular AMPH failed to induce internalization of an uptake-impaired mutant form of DAT (Y335A-hDAT); whereas direct intracellular application of AMPH via a whole cell patch pipette restored the trafficking of Y335A-hDAT, and revealed that its endocytic regulation is triggered by intracellular AMPH<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Subsequent study has identified the G-protein coupled receptor (GPCR) TAAR1 as the intracellular effector of AMPH-mediated RhoA activation and DAT endocytosis<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>.</p><p id="Par10">An essential downstream effector of RhoA activation is Arp2/3, which directly regulates actin branching and polymerization to provide the necessary force for membrane remodeling in the absence of clathrin<sup><xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup> and highlights the role of actin dynamics in DAT trafficking. Actin depolymerization agents lead to reduced DAT surface expression in striatal tissue<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Piccolo, a component of the presynaptic cytoskeletal matrix, was shown to negatively regulate methamphetamine-induced DAT internalization, possibly through sequestering membrane phosphatidylinositol 4,5-bisphosphate (PIP2)<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>.</p></sec><sec id="Sec7"><title>Lipid raft and DAT surface retention</title><p id="Par11">Lipid rafts are cholesterol- and sphingolipid-enriched microdomains on the plasma membrane. DAT is proposed to distribute equally among raft and non-raft domains<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup>. Although it is generally acknowledged that DAT association with lipid rafts negatively regulates the kinetics of the transporter activity<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup> and membrane mobility<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>, the role of lipid rafts on DAT endocytosis is controversial. While some studies report raft-associated DAT exhibits more resistance to constitutive and PKC mediated endocytosis<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, others show DAT endocytosis arises equally from raft and non-raft associated populations<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. DAT forms a stable protein complex with membrane protein flotillin-1, and that interaction appears to be required for DAT targeting to lipid rafts<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. siRNA mediated flotillin-1 knock down may block PMA-mediated DAT endocytosis in heterologous systems and mid-brain dopaminergic neuronal cultures<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Paradoxically, in an independent study, the same treatment did not exhibit any effect in PMA-treated HA-DAT expressing cells<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Lipid rafts provide a scaffold for plasma membrane protein interactions with the cytoskeleton and promote DAT clustering<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. It is possible that flotillin facilitates endocytosis by promoting DAT clustering prior to carrier formation, rather than being directly involved in carrier formation, as shown for other cargos<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup>. However, the conflicting results might be due to the model system used to study raft and non-raft associated DAT trafficking. Future studies might directly examine the trafficking routes of DAT-flotillin complexes in mid-brain dopaminergic neurons expressing DAT endogenously.</p></sec></sec><sec id="Sec8"><title>DAT post-endocytic sorting</title><p id="Par12">In general, degradative and recycling pathways are physically separated by distinct endosomal subdomains, and defined by their respective sorting machineries<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. The endosomal sorting complexes required for transport (ESCRT) family of proteins defines degradative subdomains<sup><xref ref-type="bibr" rid="CR73">73</xref></sup> and orchestrates the recruitment of ubiquitinated cargos to budding intraluminal vesicles. Conversely, tubular extensions occupy most of the membrane surface and provide subdomains enriched in cargo retrieval complexes, including the retromer and retriever complexes. These generate tubulo-vesicles for plasma membrane recycling or retrograde transport to the Golgi network<sup><xref ref-type="bibr" rid="CR74">74</xref>&#x02013;<xref ref-type="bibr" rid="CR76">76</xref></sup>. Extensive efforts have been invested to identify the subcellular localization of internalized DAT, to define its post-endocytic fate. However, the ambiguous colocalization pattern of DAT with known post-endocytic sorting markers, and lack of methodology to reliably track endogenous DAT have led to conflicting results, as reviewed below.</p><sec id="Sec9"><title>Degradation</title><p id="Par13">Although the field cannot reach a consensus on the exact post-endocytic fate of DAT, most studies provide evidence that DAT is, at least in part, targeted for lysosomal degradation following endocytosis. Studies using either antibody feeding assays or fluorescent cocaine analogs to visualize epitope-tagged or endogenous DAT in mid-brain neuronal cultures all confirm that internalized DAT partially localizes to late endosomes and lysosomes<sup><xref ref-type="bibr" rid="CR77">77</xref>&#x02013;<xref ref-type="bibr" rid="CR81">81</xref></sup>. Electron microscopy studies also show that DAT localizes to the endolysosomal compartment, albeit less in axonal terminals than in soma<sup><xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref></sup>.</p><p id="Par14">N-terminal ubiquitination may be the tag that sorts DAT to its degradative fate. DAT undergoes ubiquitylation on conserved lysine residues in heterologous systems and mid-brain neuronal cultures, which is significantly enhanced following PMA treatment<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>. Nedd4&#x02013;2 has been identified to ubiquitinate DAT in a PKC dependent manner<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Either down regulation of Nedd4-2 or abolition of DAT N&#x02019;-terminal lysines by mutagenesis impairs the PKC-mediated endocytosis of DAT<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>. However, Nedd4 regulates the trafficking and degradation of many membrane proteins so disruption of DAT trafficking could be a secondary consequence rather than a direct effect.</p><p id="Par15">Interestingly, DAT is proposed to undergo monoubiquitylation and lys63-linked polyubiquitylation<sup><xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref></sup>, both of which serve to target cargos to a degradative fate by recruiting cargo to ESCRT-positive subdomains<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. Supporting the theory, DAT localization to the ESCRT component &#x02018;hepatocyte growth factor-regulated tyrosine kinase substrate (HRS)-positive&#x02019; endosomal compartment was also confirmed in PMA treated YFP-DAT expressing cells<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. Conversely, modification that reduces DAT ubiquitination also reduces degradation and enhances DAT&#x02019;s steady state level<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>. Collectively, these studies support the model where PKC-mediated ubiquitination recruits DAT to a degradative fate.</p><p id="Par16">However, attempts to validate PKC-mediated degradation for endogenous DAT have proven challenging as multiple groups report PMA treatment fails to induce DAT internalization in mid-brain neuronal cultures<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. Although PKC-induced loss of surface DAT can be robustly reproduced using a biotinylation assay of <italic>ex-vivo</italic> striatal and mid-brain slices, the total level of DAT is not significantly reduced compared to heterologous systems<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. Conflicting results may be due to differences in PMA treatment times and/or use of heterologous model systems overexpressing DAT. More research is needed to validate DAT ubiquitination and subcellular localization in its native environments, including the soma and terminal regions of dopamine neurons.</p></sec><sec id="Sec10"><title>Recycling</title><p id="Par17">Endocytic recycling pathways for DAT also remain elusive. Early electron microscopy (EM) studies in rodent brains observed DAT immunoreactivity in tubulovesicular structures in the soma, albeit less frequently in axonal varicosities, suggesting DAT may be subject to endocytic recycling<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Although DAT exhibits partial colocalization with recycling markers, such as syntaxin13, the transferrin receptor and Rab11, in cultured mid-brain neurons and in <italic>ex-vivo</italic> slices, the extent of that colocalization is quite ambiguous compared to <italic>bona fide</italic> recycling cargos such as transferrin and &#x003b2;2-adrenergic receptors<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR80">80</xref></sup>. Direct comparison between the trafficking of DAT and norepinephrine transporter (NET, a SLC6 family transporter closely related to DAT) shows that NET is more likely to recycle via Rab11 than DAT, due to the non-conserved N&#x02019;-termini of the two transporters<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. However, in N2A neuroblastoma cells, expression of dominant-active Rab11 upregulates DAT surface expression and uptake activity<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. Multiple groups have also demonstrated DAT plasma membrane recycling with antibody feeding or biotinylation based assays in various cell lines and mid-brain neuronal cultures<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup>. In support of its recycling fate, DAT was shown localize to VPS35 positive vesicles in dopaminergic cell lines and dopamine axons in mouse medial forebrain bundle axons<sup><xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>. Either knocking down or expression of PD-linked mutant Vps35 p.D620N leads to reduced total and surface expression of DAT in heterologous systems and mouse striatal tissues<sup><xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup>, albeit without producing a PD-like motor phenotypes in this animal model<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. Internalized DAT that undergoes retromer-mediated plasma membrane recycling or retrograde trafficking may potentially account for the comparatively decreased colocalization between DAT and Rab11.</p><p id="Par18">The retromer complex orchestrates sequence-dependent cargo retrieval as opposed to sequence-independent bulk recycling<sup><xref ref-type="bibr" rid="CR92">92</xref>,<xref ref-type="bibr" rid="CR93">93</xref></sup>. However, the sequence responsible for DAT-retromer interaction remains to be determined. The PDZ domain is a well characterized recycling sequence recognized by retromer and its adaptor protein for plasma membrane recycling<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>. The same mechanism is proposed to regulate retromer-mediated recycling of DAT<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. Indeed, mice harboring mutations in the putative PDZ domain of DAT exhibit reduced surface DAT expression in the striatum<sup><xref ref-type="bibr" rid="CR94">94</xref></sup>. Furthermore, the DAT PDZ motif was required, at least partially, for exit out of retromer-positive endosomes<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. However, unlike well-characterized retromer cargos such as beta 2 adrenergic receptor (&#x003b2;2AR) or glucose transporter1 (GLUT1)<sup><xref ref-type="bibr" rid="CR95">95</xref>&#x02013;<xref ref-type="bibr" rid="CR97">97</xref></sup> which have a type I PDZ domain, DAT has a type II PDZ domain. This is unlikely to be recognized by SNX27, the adaptor protein best characterized in retromer-mediated plasma membrane recycling<sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup>. Retromer binding is sometimes facilitated by palmitoylation of cysteine residues in the cytosolic tails of cargo proteins<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>, and notably, DAT undergoes C&#x02019;-terminal cysteine palmitoylation<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>. Pharmacological inhibition or mutagenesis of those cysteine residues enhances PMA-induced downregulation of DAT in heterologous cells and rat striatal synaptosomes, suggesting palmitoylation may function to resist PKC-mediated DAT degradation<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>. The functional impact of palmitoylation on dopamine reuptake kinetics of surface DAT is well described<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>, but whether palmitoylation affects DAT endocytic sorting and trafficking is unknown.</p></sec></sec><sec id="Sec11"><title>DAT axonal targeting</title><p id="Par19">Another puzzle in DAT trafficking is the mechanism of DAT axonal targeting. Midbrain dopaminergic neurons project long and extensively arborized terminals<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. In rat a single dopaminergic neuron in the <italic>substantia nigra</italic> is estimated to influence ~75,000 striatal neurons<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, via as many as 370,000 terminal axonal boutons<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. DAT is found throughout the plasma membrane of the axons and varicosities of dopaminergic neurons<sup><xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref></sup>. It seems intuitive that with such a complex morphology, dopaminergic neurons might employ local DAT synthesis rather than long-range axonal trafficking. Surprisingly, the <italic>in-situ</italic> hybridization signal for DAT mRNA is primarily observed in the mid-brain and almost invisible in the striatum<sup><xref ref-type="bibr" rid="CR103">103</xref>,<xref ref-type="bibr" rid="CR104">104</xref></sup>, although that may reflect the probes used and the sensitivity of traditional <italic>in-situ</italic> methods. It remains possible that DAT mRNA may be found outside of the somatodendritic compartment. At the protein level, most DAT localizes to smooth endoplasmic reticulum in the soma and not in axonal terminals<sup><xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref></sup>. In mid-brain neuronal cultures from tagged HA-DAT knock-in mice, HA-DAT vesicles display rapid bi-directional movement along axons suggesting that DAT is synthesized in somal endoplasmic reticulum (ER) and subject to axonal trafficking. A recent study examined long-range DAT trafficking in medial forebrain bundle axonal tracts to reveal that most DAT is membrane localized with a more limited distribution in retromer positive vesicles<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>. The result raised the possibility that DAT might be trafficked by both membrane diffusion and vesicular transport<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>. Future studies examining DAT localization to microtubule markers and/or microtubule motor proteins such as kinesin would further clarify the mechanism of long-range DAT trafficking.</p><p id="Par20">ER export relies heavily on coated-protein complex (COPII) coat-derived vesicles with SEC24 family proteins orchestrating cargo recognition<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>. Supporting the role of SEC24-mediated ER export in DAT axonal targeting, siRNA knockdown against SEC24D in heterologous cell lines slows down dopamine reuptake<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>. In C.<italic>elegans</italic>, deletion or mutagenesis of a conserved sequence <sup>591</sup>PYRKR<sup>595</sup> in the DAT-1 C&#x02032;-terminus leads to somatic retention<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>. The PYRKR sequence contains a 3&#x02009;R motif that mediates the interaction between SEC24 and &#x003b1;2&#x003b2;-adrenergic receptor<sup><xref ref-type="bibr" rid="CR107">107</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup>, suggesting the failure of DAT-1 synaptic localization might be due to reduced interaction with SEC24-1. In HEK293 cells, mutation of the corresponding sequence in DAT does not affect its interaction with SEC24D, nor significantly reduces DAT surface expression, but does disrupt the ability of SEC24D to enhance DAT surface expression<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>. However, HEK293 cells are not going to be an informative model for DAT axonal trafficking as they lack the bipolar morphology of dopaminergic neurons.</p><p id="Par21">In conclusion, multiple molecular mechanisms are implicated in DAT trafficking and the specific trafficking route is highly dependent on signaling. Key mechanisms are summarized in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. DAT trafficking studies have suffered from a lack of reagents to reliably track DAT in its native environment, and work conducted in heterologous systems had often produced conflicting results. More recent super-resolution microscopy has revealed the dynamic localization of neuronal transmembrane proteins, including DAT<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR109">109</xref>,<xref ref-type="bibr" rid="CR110">110</xref></sup>, and may prove useful to dissect mechanisms governing endogenous DAT trafficking in <italic>bona fide</italic> dopaminergic terminals.<fig id="Fig1"><label>Fig. 1</label><caption><title>Dopamine transporter surface expression is regulated through endocytic trafficking.</title><p>RIT2-DAT association acts as DAT endocytic brake. PKC activation promotes the dissociation of RIT2 from DAT, enhances DAT ubiquitination by Nedd2-4, and targets DAT to clathrin-mediated endocytosis. Ubiquitinated DAT is recruited to ESCRT-Hrs complex which sorts DAT for lysosomal degradation. Conversely, DAT substrate activates intracellular effector TAAR1 and RhoA GTPase, which orchestrates actin polymerization through Arp2/3 near the plasma membrane and mediates clathrin-independent endocytosis. Substrate induced DAT internalization preferentially targets DAT to Rab11 mediated plasma membrane recycling, possibly through retromer-WASH (the endosomal cargo retrieval complex). This figure is created with BioRender.com.</p></caption><graphic xlink:href="41531_2021_161_Fig1_HTML" id="d32e998"/></fig></p></sec><sec id="Sec12"><title>The dopamine transporter, monogenic parkinsonism, and models</title><p id="Par22">Given the complex morphology of dopaminergic neurons and the onerous burden of long-term axonal trafficking, it is tempting to speculate that endocytic dysregulation of the dopaminergic transporter may lead to the selective vulnerability of dopaminergic neurons in PD. In this section, monogenic parkinsonism, and models based on those gene linkages are reviewed, albeit focused on their DAT biology. Most mice that model human gene mutations linked to PD do not exhibit overt motor symptoms but many have subtle alterations to their dopaminergic system, as illustrated in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Mouse models of genes implicated in Parkinson&#x02019;s disease and their dopamine neurotransmission phenotypes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Model</th><th>Motor symptom</th><th>Dopamine neurotransmission phenotype</th><th>Proposed role in DAT regulation</th></tr></thead><tbody><tr><td rowspan="4">SNCA</td><td>mThy-1 human WT &#x003b1;-synuclein overexpression<sup><xref ref-type="bibr" rid="CR112">112</xref></sup></td><td>L-Dopa responsive sensorimotor deficits</td><td>Increased extracellular dopamine; increased dopamine turnover rate; lower striatal TH level</td><td rowspan="4">Membrane microdomain targeting<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>, and surface insertion<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR122">122</xref></sup>.</td></tr><tr><td>(AAV6)&#x02013; human WT &#x003b1;-synuclein<sup><xref ref-type="bibr" rid="CR116">116</xref></sup></td><td>Age-dependent motor deficits</td><td>Reduced striatal dopamine release and dopamine reuptake; reduced dopamine tissue levels;</td></tr><tr><td>CaM-tTA human WT &#x003b1;-synuclein overexpression<sup><xref ref-type="bibr" rid="CR115">115</xref></sup></td><td>Age-dependent motor deficit</td><td>Significant reduction of dopamine level in the olfactory bulb; Trend towards reduced dopamine in striatum; loss of dopamine neurons in SN.pc</td></tr><tr><td>MPrion human A53T &#x003b1;-synuclein overexpression<sup><xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR114">114</xref></sup></td><td>Motor hyperactivity</td><td>Reduced DAT expression and dopamine reuptake; Increased dopamine content in striatal tissue; no evident loss of dopamine neuron in SN.pc</td></tr><tr><td rowspan="5">LRRK2</td><td>BAC human LRRK2 overexpression<sup><xref ref-type="bibr" rid="CR176">176</xref></sup></td><td>Motor hyperactivity</td><td>Elevated striatal dopamine release; comparable dopamine uptake and tissue dopamine content; no loss of dopamine neurons in SN.pc</td><td rowspan="5">Long term axonal trafficking<sup><xref ref-type="bibr" rid="CR132">132</xref></sup>, endolysosomal trafficking<sup><xref ref-type="bibr" rid="CR149">149</xref></sup></td></tr><tr><td>BAC human LRRK2 R1441G<sup><xref ref-type="bibr" rid="CR177">177</xref></sup></td><td>L-DOPA responsive motor deficits</td><td>Reduced striatal dopamine release; no evident loss of dopamine neuron in SN.pc</td></tr><tr><td>Human LRRK2 G2019S transgene<sup><xref ref-type="bibr" rid="CR178">178</xref></sup></td><td>Age-dependent motor deficits</td><td>Normal striatal dopamine level and turnover rate; Increased dopamine turnover rate in olfactory bulb; Age-dependent loss of dopamine neurons in SN.pc</td></tr><tr><td>Mouse Lrrk2 R1441C knock-in<sup><xref ref-type="bibr" rid="CR179">179</xref></sup></td><td>Decreased locomotor responses to quinpirole; reduced locomotor response to AMPH</td><td>Normal striatal dopamine level; reduced catecholamine release; no loss of dopamine neurons in SN.pc</td></tr><tr><td>Mouse Lrrk2 G2019S knockin<sup><xref ref-type="bibr" rid="CR127">127</xref>,<xref ref-type="bibr" rid="CR128">128</xref></sup></td><td>Early hyperactivity that declines with age<sup><xref ref-type="bibr" rid="CR128">128</xref></sup></td><td>Reduced striatal dopamine release; trend of reduced DAT expression; age-dependent DAT dysfunction; increased dopamine turnover rate; no loss of dopamine neurons in SN.pc</td></tr><tr><td>VPS35</td><td>Mouse Vps35 D620N knockin<sup><xref ref-type="bibr" rid="CR91">91</xref></sup></td><td>No evident motor symptoms</td><td>Altered striatal dopamine release; reduced dopamine reuptake; reduced striatal DAT expression; no evident loss of dopamine neurons in SN.pc</td><td>DAT endocytic sorting and recycling<sup><xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup></td></tr><tr><td>PARKIN</td><td>Mouse Parkin knockout<sup><xref ref-type="bibr" rid="CR158">158</xref>,<xref ref-type="bibr" rid="CR159">159</xref></sup></td><td>Reduced spontaneous motor activity</td><td>Increased dopamine turnover; Increased extracellular dopamine; Reduced striatal dopamine release; reduced dopamine reuptake; no loss of dopamine neurons in SN.pc</td><td>Protein quality control<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>; endolysosomal trafficking<sup><xref ref-type="bibr" rid="CR155">155</xref>,<xref ref-type="bibr" rid="CR156">156</xref></sup></td></tr><tr><td>RIT2</td><td>Mouse <italic>Pitx3</italic><sup><italic>IRES2-tTA</italic></sup>
<italic>RIT2 knockout</italic><sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR166">166</xref></sup></td><td>Increased acute cocaine sensitivity in males, but decreased in females</td><td>In females: reduced surface DAT expression in ventral striatum; In males: reduced total DAT levels; increased [<sup>3</sup>H] dopamine reuptake in striatal slices</td><td>DAT surface retention<sup><xref ref-type="bibr" rid="CR29">29</xref></sup></td></tr></tbody></table><table-wrap-foot><p>The literature cited is not exhaustive. However, reduced DAT-mediated dopamine reuptake is frequently observed in mouse models without dopaminergic degeneration.</p></table-wrap-foot></table-wrap></p><sec id="Sec13"><title>SNCA</title><p id="Par23">&#x003b1;-synuclein (SNCA) is a presynaptic protein and a major component of Lewy pathology. Studies of familial forms of Parkinson&#x02019;s disease have identified <italic>SNCA</italic> missense mutations and genomic multiplications<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. Mice models overexpressing mutant or wild type human &#x003b1;-synuclein mostly exhibit reduced DAT expression and dopamine reuptake<sup><xref ref-type="bibr" rid="CR112">112</xref>&#x02013;<xref ref-type="bibr" rid="CR116">116</xref></sup> with some exceptions<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. &#x003b1;-synuclein may form a stable complex with DAT in heterologous systems, rodent and human striatal tissues<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup>. Studies in dopaminergic neuronal cultures suggest DAT/&#x003b1;-synuclein association negatively regulates DAT reuptake activity<sup><xref ref-type="bibr" rid="CR120">120</xref>&#x02013;<xref ref-type="bibr" rid="CR122">122</xref></sup> possibly by redistributing surface DAT to cholesterol-rich microdomains and altering ionic coupling of DAT mediated current<sup><xref ref-type="bibr" rid="CR120">120</xref>,<xref ref-type="bibr" rid="CR121">121</xref></sup>. DAT surface expression, measured by biotinylation, is also reduced with co-expression of wild type &#x003b1;-synuclein<sup><xref ref-type="bibr" rid="CR123">123</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup>. When compared to wild type &#x003b1;-synuclein, the PD-linked missense mutation <italic>SNCA</italic> p.A30P enhances DAT &#x003b1;-synuclein interaction and further reduces DAT surface expression and function; in contrast, p.A53T does not form a strong protein-protein complex with DAT, nor modulates DAT function or surface expression. Although <italic>SNCA</italic> p.A30P and p.A53T have disparate effects on DAT-binding and trafficking, they are N&#x02019;-terminal located on the hydrophobic face of &#x003b1;-synuclein&#x02019;s amphipathic helix, highlighting the importance of maintaining that protein-lipid interaction.</p></sec><sec id="Sec14"><title>LRRK2</title><p id="Par24">Leucine-rich repeat kinase 2 (LRRK2), encodes a large multidomain protein containing kinase and GTPase enzymatic activities. LRRK2 genetic variability is found throughout the gene but pathogenic mutations cluster in the Roc-COR and kinase domains, and account for this common form of familial parkinsonism<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. All mutations lead to upregulation of LRRK2 kinase activity. Investigations of in vivo dopaminergic function with PET imaging consistently reveal increased dopamine turnover rates in asymptomatic LRRK2 heterozygotes<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR125">125</xref></sup>. Interestingly, those asymptomatic individuals showed reduced DAT levels, measured by the commonly used PET tracer 11C-d-threo-methylphenidate (<sup>11</sup>C-MP)<sup><xref ref-type="bibr" rid="CR125">125</xref></sup>, suggesting early dysfunction of DAT in the absence of significant loss of dopamine synthesis and storage. In rodent models, temporal overexpression of human LRRK2 p.G2019S in dopaminergic neurons impairs DAT mediated dopamine reuptake<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>. Constitutive Lrrk2 p.G2019S knock-in mice also exhibit impairment in striatal dopamine reuptake at various ages<sup><xref ref-type="bibr" rid="CR127">127</xref>,<xref ref-type="bibr" rid="CR128">128</xref></sup>. Although there are limited number of studies that directly examine the role of LRRK2 in DAT regulation, growing evidence has established LRRK2 as an important regulator of intracellular membrane trafficking<sup><xref ref-type="bibr" rid="CR129">129</xref></sup>, at a nexus between actin-dependent and tubulin-dependent cargo transport<sup><xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR132">132</xref></sup>. Mutant LRRK2 leads to dysregulated endocytic sorting<sup><xref ref-type="bibr" rid="CR133">133</xref></sup> through phosphorylation of Rab proteins<sup><xref ref-type="bibr" rid="CR134">134</xref>,<xref ref-type="bibr" rid="CR135">135</xref></sup> whose coordinated action critically regulates vesicular transport and endosome maturation<sup><xref ref-type="bibr" rid="CR136">136</xref>,<xref ref-type="bibr" rid="CR137">137</xref></sup>. LRRK2 binding to microtubules is also associated with tau phosphorylation<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR139">139</xref></sup>, microtubule acetylation<sup><xref ref-type="bibr" rid="CR132">132</xref>,<xref ref-type="bibr" rid="CR140">140</xref></sup> and impaired axonal transport<sup><xref ref-type="bibr" rid="CR132">132</xref></sup>. Hence, DAT endosomal recycling and axonal trafficking may be dysregulated by chronic LRRK2 hyperactivity. Exploring the increased (or compensatory) dopamine turnover observed in asymptomatic LRRK2 heterozygous individuals may provide mechanistic insight into the physiological and pathological role of LRRK2 in DAT regulation.</p></sec><sec id="Sec15"><title>VPS35</title><p id="Par25">VPS35 is a component of the retromer complex required for recycling cargo protein in the early endosome to the trans-Golgi network or plasma membrane<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. A missense mutation, VPS35 p.D620N has been linked to a familial form of parkinsonism that is clinically indistinguishable from idiopathic late-onset PD<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR142">142</xref></sup>. VPS35 colocalizes with DAT and mediates DAT plasma membrane recycling both in vitro and in vivo<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. Mice harboring Vps35 p.D620N exhibit reduced striatal DAT expression and altered striatal dopamine neurotransmission in the absence of motor deficits or neurodegeneration<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. Although the exact pathological mechanism of VPS35 p.D620N remains elusive, multiple studies show the mutation disrupts the interaction between VPS35 and the WASH complex<sup><xref ref-type="bibr" rid="CR143">143</xref>,<xref ref-type="bibr" rid="CR144">144</xref></sup> whose primary function is to coordinate actin branching and stabilize endosomal subdomains for VPS35-mediated cargo sorting of recycling proteins<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. Failure to adequately recruit or retain WASH complex may lead to the mis-sorting of DAT, as illustrated by other retromer cargos<sup><xref ref-type="bibr" rid="CR143">143</xref>,<xref ref-type="bibr" rid="CR145">145</xref>,<xref ref-type="bibr" rid="CR146">146</xref></sup>. These data are consistent with the hypothesis that expression of VPS35 p.D620N can impair DAT recruitment and recycling.</p><p id="Par26">Increasing evidence suggests that VPS35 and LRRK2 functionally interact and converge on endocytic trafficking. VPS35 and LRRK2 directly interact, decorate endosomes, and may work in concert in synaptic vesicle recycling<sup><xref ref-type="bibr" rid="CR147">147</xref></sup>. VPS35 p.D620N significantly elevates LRRK2-mediated phosphorylation of Rab proteins in mouse brain and human neutrophils<sup><xref ref-type="bibr" rid="CR148">148</xref></sup>. Endolysosomal dysfunction induced by mutant LRRK2 can be rescued by overexpression of VPS35<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>, although toxic to synapses in primary culture<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>. Given VPS35 and LRRK2 mouse models exhibit similar deficits in DAT mediated reuptake, it is possible that they also cooperate in the regulation of DAT trafficking. Interestingly, acute treatment with the LRRK2 kinase inhibitor, MLi2, in Vps35 p.D620N knock-in mice rescues the reduction in striatal DAT levels and the reduction in dopamine reuptake<sup><xref ref-type="bibr" rid="CR91">91</xref></sup> (Farrer lab, unpublished data). However, it is currently unknown which step in DAT trafficking (e.g., endocytosis, endocytic sorting, axonal targeting) is involved and whether VPS35 and LRRK2 work in concert or in competition.</p></sec><sec id="Sec16"><title>Parkin</title><p id="Par27">Parkin is a protein-ubiquitin E3 ligase which ubiquitinates and targets substrate to proteasome degradation<sup><xref ref-type="bibr" rid="CR150">150</xref></sup>. Mutations in Parkin lead to loss of function of its ubiquitin ligase activity and are linked to autosomal recessively inherited, early-onset Parkinson&#x02019;s disease with a central role in mitophagy<sup><xref ref-type="bibr" rid="CR151">151</xref></sup>. However, patients with mutations in Parkin often exhibit a marked reduction of DAT expression or uptake activity<sup><xref ref-type="bibr" rid="CR152">152</xref>,<xref ref-type="bibr" rid="CR153">153</xref></sup>. DAT ubiquitination was previously shown to be increased in Parkin transfected human dopaminergic SH-SY5Y cells<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. WT Parkin, but not PD-linked mutants, significantly increase DAT surface expression and dopamine reuptake, and possibly enhance degradation of misfolded DAT<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. An association between Parkin and DAT has also been shown to disrupt the interaction between DAT and &#x003b1;-synculein<sup><xref ref-type="bibr" rid="CR154">154</xref></sup>; however, further validation using a more sensitive approach, such as F&#x000f6;rster resonance energy transfer (FRET) or yeast 2-hybrid methods, is warranted. Parkin is reported to ubiquitinate Rab7, Eps15, and VPS35 and so contributes to the regulation of the endo-lysosomal pathway<sup><xref ref-type="bibr" rid="CR155">155</xref>&#x02013;<xref ref-type="bibr" rid="CR157">157</xref></sup>. Parkin knock-out mice exhibit reduced striatal levels of DAT and dopamine uptake<sup><xref ref-type="bibr" rid="CR158">158</xref>,<xref ref-type="bibr" rid="CR159">159</xref></sup>. In patient-derived IPSCs, loss of Parkin function also leads to reduced [<sup>3</sup>H]CFT (2-&#x003b2;-carbomethoxy-3-&#x003b2;-(4-fluorophenyl)tropane, a cocaine analog) binding to DAT and increased Ca<sup>2+</sup>-independent dopamine release, potentially via a reverse transport mechanism<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>. Several studies support the hypothesis in which loss of parkin function reduces DAT activity either directly, through impaired protein quality control, or indirectly through dysregulation of DAT endocytic trafficking.</p></sec><sec id="Sec17"><title>RIT2</title><p id="Par28"><italic>RIT2</italic> was identified as a PD risk gene in multiple GWAS studies and in different ethnic groups<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR161">161</xref>&#x02013;<xref ref-type="bibr" rid="CR164">164</xref></sup>, and Rit2 expression is significantly reduced in the <italic>substantia nigra</italic> of PD patients<sup><xref ref-type="bibr" rid="CR165">165</xref></sup>. Rit2 encodes a small neuronal GTPase that associates with DAT and may act as DAT endocytic brake<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Studies in heterologous systems reveal RIT2 associates with the C-terminus of DAT, but not SERT, and that RIT2 GTPase activity is critical for PKC-mediated DAT internalization<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Although Rit2 was shown to co-immunoprecipitate with DAT in mouse striatum<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> this result appears to be an artifact as the antibody used was unspecific<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Nevertheless, the effects of Rit2 in <italic>bona fide</italic> dopaminergic terminals are confirmed in mouse striatal slices<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. In <italic>Pitx3</italic><sup><italic>IRES2-tTA</italic></sup> shRit2 mice, where Rit2 is selectively knockdown in dopaminergic neurons, PKC-stimulated DAT internalization in acute striatal slices is significantly reduced<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Interestingly, <italic>Pitx3</italic><sup><italic>IRES2-tTA</italic></sup> shRit2 mice exhibit sex-dimorphism in dopamine related phenotypes<sup><xref ref-type="bibr" rid="CR166">166</xref></sup>. Conditional Rit2 knockout leads to a blunted response to acute cocaine treatment in female mice, but an increased response in males<sup><xref ref-type="bibr" rid="CR166">166</xref></sup>. Accordingly, [<sup>3</sup>H] dopamine uptake in male striatal slices is enhanced without significant change in surface DAT expression<sup><xref ref-type="bibr" rid="CR166">166</xref></sup>, whereas in females surface DAT is reduced in the ventral striatum<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Considering the important role of sex in DAT function and PD risk<sup><xref ref-type="bibr" rid="CR167">167</xref>&#x02013;<xref ref-type="bibr" rid="CR172">172</xref></sup>, RIT2 poses a promising target to study the effect of sexual dimorphism in DAT regulation and in the etiology of PD.</p></sec></sec><sec id="Sec18"><title>Concluding remarks</title><p id="Par29">A variety of signaling pathways have been identified that dynamically regulate dopamine reuptake through DAT plasma membrane trafficking, and many overlap with key molecular mechanisms compromised by PD-linked mutations as illustrated in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. Down regulation of DAT-mediated dopamine reuptake and increase in striatal dopamine release are often observed in genetic models of parkinsonism. Why would the neurons employ so many complicated signaling pathways to regulate DAT trafficking? DAT critically maintains dopamine homeostasis to regulate dopamine signaling that is absolutely required for movement initiation and survival. Cytosolic dopamine is also easily oxidized, may lead to the production of free radicals, and drives neuromelanin biosynthesis<sup><xref ref-type="bibr" rid="CR173">173</xref></sup>. Direct administration of dopamine and overexpression of dopamine transporter both lead to neuronal loss<sup><xref ref-type="bibr" rid="CR174">174</xref>,<xref ref-type="bibr" rid="CR175">175</xref></sup>. Conversely, dopamine reuptake by DAT is the primary mechanism for the maintenance of dopamine storage, and loss of DAT leads to dopamine depletion<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The depolarizing currents generated by dopamine reuptake also directly regulate the excitability of presynaptic boutons<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Thus, DAT surface expression must be controlled to allow dopaminergic neurons to optimally function. The complexities of DAT regulation may enable multiple compensatory mechanisms to maintain dopamine signaling despite early dysfunction. Given the role of DAT in the regulation of dopamine release and the long-hypothesized connection between altered dopamine neurotransmission and PD, studies of DAT regulation in physiological and pathological conditions remain a promising avenue to identify early biomarkers and therapeutic targets for PD.<fig id="Fig2"><label>Fig. 2</label><caption><title>A model for the physiological and pathological roles of PD-lined genes in DAT regulation.</title><p>Dopamine transporter trafficking is regulated by various mechanisms, many of which overlap with key molecular mechanisms compromised by PD-linked mutations. &#x003b1;-synuclein and Rit2 interact with DAT and regulate both surface expression and dopamine uptake kinetics. LRRK2 may regulate DAT trafficking either through axonal transport and/or endocytic trafficking. Parkin is proposed to ubiquitinate improperly folded DAT and increase its turnover rate. VPS35 is responsible for recruiting internalized DAT to a recycling fate. This figure is created with BioRender.com.</p></caption><graphic xlink:href="41531_2021_161_Fig2_HTML" id="d32e1699"/></fig></p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>M.B. prepared the manuscript. H.K. and M.J.F. supervised and revised the manuscript.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wile</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies</article-title><source>Lancet Neurol.</source><year>2017</year><volume>16</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30056-X</pub-id><?supplied-pmid 28336296?><pub-id pub-id-type="pmid">28336296</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Dopamine turnover increases in asymptomatic LRRK2 mutations carriers</article-title><source>Mov. Disord.</source><year>2010</year><volume>25</volume><fpage>2717</fpage><lpage>2723</lpage><pub-id pub-id-type="doi">10.1002/mds.23356</pub-id><?supplied-pmid 20939082?><pub-id pub-id-type="pmid">20939082</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CS</given-names></name><etal/></person-group><article-title>In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson&#x02019;s disease</article-title><source>Ann. Neurol.</source><year>2000</year><volume>47</volume><fpage>493</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(200004)47:4&#x0003c;493::AID-ANA13&#x0003e;3.0.CO;2-4</pub-id><?supplied-pmid 10762161?><pub-id pub-id-type="pmid">10762161</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Increase in dopamine turnover occurs early in Parkinson&#x02019;s disease: evidence from a new modeling approach to PET 18F-fluorodopa data</article-title><source>J. Cereb. Blood Flow. Metab.</source><year>2002</year><volume>22</volume><fpage>232</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1097/00004647-200202000-00011</pub-id><?supplied-pmid 11823721?><pub-id pub-id-type="pmid">11823721</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>W</given-names></name><etal/></person-group><article-title>Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum</article-title><source>J. Neurosci.</source><year>2009</year><volume>29</volume><fpage>444</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4029-08.2009</pub-id><?supplied-pmid 19144844?><pub-id pub-id-type="pmid">19144844</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbuthnott</surname><given-names>GW</given-names></name><name><surname>Wickens</surname><given-names>J</given-names></name></person-group><article-title>Space, time and dopamine</article-title><source>Trends Neurosci.</source><year>2007</year><volume>30</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2006.12.003</pub-id><?supplied-pmid 17173981?><pub-id pub-id-type="pmid">17173981</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>ME</given-names></name><name><surname>Cragg</surname><given-names>SJ</given-names></name></person-group><article-title>Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway</article-title><source>Brain Res. Rev.</source><year>2008</year><volume>58</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.brainresrev.2008.02.004</pub-id><?supplied-pmid 18433875?><pub-id pub-id-type="pmid">18433875</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>SJ</given-names></name><name><surname>Rice</surname><given-names>ME</given-names></name></person-group><article-title>DAncing past the DAT at a DA synapse</article-title><source>Trends Neurosci.</source><year>2004</year><volume>27</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2004.03.011</pub-id><?supplied-pmid 15111009?><pub-id pub-id-type="pmid">15111009</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Dopamine receptor subtypes: beyond the D1/D2 classification</article-title><source>Trends Pharmacol. Sci.</source><year>1990</year><volume>11</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/0165-6147(90)90249-8</pub-id><?supplied-pmid 2200181?><pub-id pub-id-type="pmid">2200181</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciliax</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Immunocytochemical localization of the dopamine transporter in human brain</article-title><source>J. Comp. Neurol.</source><year>1999</year><volume>409</volume><fpage>38</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19990621)409:1&#x0003c;38::AID-CNE4&#x0003e;3.0.CO;2-1</pub-id><?supplied-pmid 10363710?><pub-id pub-id-type="pmid">10363710</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciliax</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>The dopamine transporter: Immunochemical characterization and localization in brain</article-title><source>J. Neurosci.</source><year>1995</year><volume>15</volume><fpage>1714</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.15-03-01714.1995</pub-id><?supplied-pmid 7534339?><pub-id pub-id-type="pmid">7534339</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>S</given-names></name><name><surname>Kitayama</surname><given-names>S</given-names></name><name><surname>Walther</surname><given-names>D</given-names></name><name><surname>Uhl</surname><given-names>G</given-names></name></person-group><article-title>Dopamine transporter mRNA: dense expression in ventral midbrain neurons</article-title><source>Mol. Brain Res.</source><year>1992</year><volume>13</volume><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/0169-328X(92)90220-6</pub-id><?supplied-pmid 1352613?><pub-id pub-id-type="pmid">1352613</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Profound neuronal plasticity in response to inactivation of the dopamine transporter</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>4029</fpage><lpage>4034</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.7.4029</pub-id><?supplied-pmid 9520487?><pub-id pub-id-type="pmid">9520487</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname><given-names>SL</given-names></name><name><surname>Prasad</surname><given-names>BM</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><article-title>Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons</article-title><source>Nat. Neurosci.</source><year>2002</year><volume>5</volume><fpage>971</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1038/nn920</pub-id><?supplied-pmid 12352983?><pub-id pub-id-type="pmid">12352983</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvelli</surname><given-names>L</given-names></name><name><surname>McDonald</surname><given-names>PW</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>DeFelice</surname><given-names>LJ</given-names></name></person-group><article-title>Dopamine transporters depolarize neurons by a channel mechanism</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>16046</fpage><lpage>16051</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403299101</pub-id><?supplied-pmid 15520385?><pub-id pub-id-type="pmid">15520385</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlig</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Amphetamine induces dopamine efflux through a dopamine transporter channel</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>3495</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407737102</pub-id><?supplied-pmid 15728379?><pub-id pub-id-type="pmid">15728379</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condon</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-12264-9</pub-id><pub-id pub-id-type="pmid">30602773</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurian</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia</article-title><source>J. Clin. Invest.</source><year>2009</year><volume>119</volume><fpage>1595</fpage><lpage>1603</lpage><?supplied-pmid 19478460?><pub-id pub-id-type="pmid">19478460</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Missense dopamine transporter mutations associate with adult parkinsonism and ADHD</article-title><source>J. Clin. Invest.</source><year>2014</year><volume>124</volume><fpage>3107</fpage><lpage>3120</lpage><pub-id pub-id-type="doi">10.1172/JCI73778</pub-id><?supplied-pmid 24911152?><pub-id pub-id-type="pmid">24911152</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiCarlo</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors</article-title><source>J. Clin. Invest.</source><year>2019</year><volume>129</volume><fpage>3407</fpage><lpage>3419</lpage><pub-id pub-id-type="doi">10.1172/JCI127411</pub-id><?supplied-pmid 31094705?><pub-id pub-id-type="pmid">31094705</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazei-Robison</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Anomalous dopamine release associated with a human dopamine transporter coding variant</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>7040</fpage><lpage>7046</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0473-08.2008</pub-id><?supplied-pmid 18614672?><pub-id pub-id-type="pmid">18614672</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazei-Robison</surname><given-names>MS</given-names></name><name><surname>Couch</surname><given-names>RS</given-names></name><name><surname>Shelton</surname><given-names>RC</given-names></name><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name></person-group><article-title>Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder</article-title><source>Neuropharmacology</source><year>2005</year><volume>49</volume><fpage>724</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.08.003</pub-id><?supplied-pmid 16171832?><pub-id pub-id-type="pmid">16171832</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>JD</given-names></name><name><surname>Cervinski</surname><given-names>MA</given-names></name><name><surname>Gorentla</surname><given-names>BK</given-names></name><name><surname>Vaughan</surname><given-names>RA</given-names></name></person-group><article-title>Regulation of the dopamine transporter by phosphorylation</article-title><source>Handb. Exp. Pharmacol.</source><year>2006</year><volume>175</volume><fpage>197</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1007/3-540-29784-7_10</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorkina</surname><given-names>T</given-names></name><etal/></person-group><article-title>RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis</article-title><source>J. Neurosci.</source><year>2006</year><volume>26</volume><fpage>8195</fpage><lpage>8205</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1301-06.2006</pub-id><?supplied-pmid 16885233?><pub-id pub-id-type="pmid">16885233</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>FJS</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Pristupa</surname><given-names>ZB</given-names></name><name><surname>Niznik</surname><given-names>HB</given-names></name></person-group><article-title>Direct binding and functional coupling of &#x003b1;&#x02010;synuclein to the dopamine transporters accelerate dopamine&#x02010;induced apoptosis</article-title><source>FASEB J.</source><year>2001</year><volume>15</volume><fpage>916</fpage><lpage>926</lpage><?supplied-pmid 11292651?><pub-id pub-id-type="pmid">11292651</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name></person-group><article-title>Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>54380</fpage><lpage>54386</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409282200</pub-id><?supplied-pmid 15492001?><pub-id pub-id-type="pmid">15492001</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremona</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT</article-title><source>Nat. Neurosci.</source><year>2011</year><volume>14</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nn.2781</pub-id><?supplied-pmid 21399631?><pub-id pub-id-type="pmid">21399631</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>RA</given-names></name><name><surname>Foster</surname><given-names>JD</given-names></name></person-group><article-title>Mechanisms of dopamine transporter regulation in normal and disease states</article-title><source>Trends Pharmacol. Sci.</source><year>2013</year><volume>34</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2013.07.005</pub-id><?supplied-pmid 23968642?><pub-id pub-id-type="pmid">23968642</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navaroli</surname><given-names>DM</given-names></name><etal/></person-group><article-title>The plasma membrane-associated gtpase rin interacts with the dopamine transporter and is required for protein kinase c-regulated dopamine transporter trafficking</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>13758</fpage><lpage>13770</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2649-11.2011</pub-id><?supplied-pmid 21957239?><pub-id pub-id-type="pmid">21957239</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Dopamine transporter trafficking and Rit2 GTPase: Mechanism of action and in vivo impact</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>5229</fpage><lpage>5244</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.012628</pub-id><?supplied-pmid 32132171?><pub-id pub-id-type="pmid">32132171</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Genome-wide association study of Parkinson&#x02019;s disease in East Asians</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>226</fpage><lpage>232</lpage><?supplied-pmid 28011712?><pub-id pub-id-type="pmid">28011712</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankratz</surname><given-names>N</given-names></name><etal/></person-group><article-title>Meta-analysis of Parkinson&#x02019;s Disease: Identification of a novel locus, RIT2</article-title><source>Ann. Neurol.</source><year>2012</year><volume>71</volume><fpage>370</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1002/ana.22687</pub-id><?supplied-pmid 22451204?><pub-id pub-id-type="pmid">22451204</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>MH</given-names></name><name><surname>Bahar</surname><given-names>I</given-names></name></person-group><article-title>Monoamine transporters: structure, intrinsic dynamics and allosteric regulation</article-title><source>Nat. Struct. Mol. Biol.</source><year>2019</year><volume>26</volume><fpage>545</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/s41594-019-0253-7</pub-id><?supplied-pmid 31270469?><pub-id pub-id-type="pmid">31270469</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penmatsa</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>KH</given-names></name><name><surname>Gouaux</surname><given-names>E</given-names></name></person-group><article-title>X-ray structure of dopamine transporter elucidates antidepressant mechanism</article-title><source>Nature</source><year>2013</year><volume>503</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nature12533</pub-id><?supplied-pmid 24037379?><pub-id pub-id-type="pmid">24037379</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastrup</surname><given-names>H</given-names></name><name><surname>Karlin</surname><given-names>A</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name></person-group><article-title>Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>10055</fpage><lpage>10060</lpage><pub-id pub-id-type="doi">10.1073/pnas.181344298</pub-id><?supplied-pmid 11526230?><pub-id pub-id-type="pmid">11526230</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastrup</surname><given-names>H</given-names></name><name><surname>Sen</surname><given-names>N</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name></person-group><article-title>The human dopamine transporter forms a tetramer in the plasma membrane: Cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>45045</fpage><lpage>45048</lpage><pub-id pub-id-type="doi">10.1074/jbc.C300349200</pub-id><?supplied-pmid 14519759?><pub-id pub-id-type="pmid">14519759</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorkina</surname><given-names>T</given-names></name><name><surname>Doolen</surname><given-names>S</given-names></name><name><surname>Galperin</surname><given-names>E</given-names></name><name><surname>Zahniser</surname><given-names>NR</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>28274</fpage><lpage>28283</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210652200</pub-id><?supplied-pmid 12746456?><pub-id pub-id-type="pmid">12746456</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Reith</surname><given-names>MEA</given-names></name></person-group><article-title>Substrates dissociate dopamine transporter oligomers</article-title><source>J. Neurochem.</source><year>2008</year><volume>105</volume><fpage>910</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05195.x</pub-id><?supplied-pmid 18088380?><pub-id pub-id-type="pmid">18088380</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dopamine transporter oligomerization: Impact of combining protomers with differential cocaine analog binding affinities</article-title><source>J. Neurochem.</source><year>2015</year><volume>133</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1111/jnc.13025</pub-id><?supplied-pmid 25580950?><pub-id pub-id-type="pmid">25580950</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbek-Clemmensen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Super-resolution microscopy reveals functional organization of dopamine transporters into cholesterol and neuronal activity-dependent nanodomains</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41467-017-00790-3</pub-id><pub-id pub-id-type="pmid">28232747</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Dopamine transporter forms stable dimers in the live cell plasma membrane in a phosphatidylinositol 4,5-bisphosphate independent manner</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>5632</fpage><lpage>5642</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.006178</pub-id><?supplied-pmid 30705091?><pub-id pub-id-type="pmid">30705091</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Sorkina, T., Ma, S., Larsen, M. B., Watkins, S. C. &#x00026; Sorkin, A. Small molecule induced oligomerization, clustering and clathrin-independent endocytosis of the dopamine transporter. <italic>Elife</italic><bold>7</bold>, e32293 (2018).</mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Jayaraman, K. <italic>et al</italic>. SLC6 transporter oligomerization. <italic>J. Neurochem</italic>, (2020), 10.1111/jnc.15145.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorkina</surname><given-names>T</given-names></name><name><surname>Hoover</surname><given-names>BR</given-names></name><name><surname>Zahniser</surname><given-names>NR</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism</article-title><source>Traffic</source><year>2005</year><volume>6</volume><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2005.00259.x</pub-id><?supplied-pmid 15634215?><pub-id pub-id-type="pmid">15634215</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>GM</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><article-title>Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>35794</fpage><lpage>35801</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.50.35794</pub-id><?supplied-pmid 10585462?><pub-id pub-id-type="pmid">10585462</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>RR</given-names></name><name><surname>Kearney</surname><given-names>PJ</given-names></name><name><surname>Melikian</surname><given-names>HE</given-names></name></person-group><article-title>In situ regulated dopamine transporter trafficking: there&#x02019;s no place like home</article-title><source>Neurochem. Res.</source><year>2020</year><volume>45</volume><fpage>1335</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1007/s11064-020-03001-6</pub-id><?supplied-pmid 32146647?><pub-id pub-id-type="pmid">32146647</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Bellve</surname><given-names>KD</given-names></name><name><surname>Fogarty</surname><given-names>KE</given-names></name><name><surname>Melikian</surname><given-names>HE</given-names></name></person-group><article-title>Ack1 is a dopamine transporter endocytic brake that rescues a trafficking-dysregulated ADHD coding variant</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>15480</fpage><lpage>15485</lpage><pub-id pub-id-type="doi">10.1073/pnas.1512957112</pub-id><?supplied-pmid 26621748?><pub-id pub-id-type="pmid">26621748</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuorenp&#x000e4;&#x000e4;</surname><given-names>A</given-names></name><etal/></person-group><article-title>Differential internalization rates and postendocytic sorting of the norepinephrine and dopamine transporters are controlled by structural elements in the N termini</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>5634</fpage><lpage>5651</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.702050</pub-id><?supplied-pmid 26786096?><pub-id pub-id-type="pmid">26786096</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrie</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: Differential dependence on dynamin and the actin cytoskeleton</article-title><source>J. Neurosci.</source><year>2013</year><volume>33</volume><fpage>17836</fpage><lpage>17846</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3284-13.2013</pub-id><pub-id pub-id-type="pmid">24198373</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorkina</surname><given-names>T</given-names></name><name><surname>Caltagarone</surname><given-names>J</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Flotillins regulate membrane mobility of the dopamine transporter but are not required for its protein kinase C dependent endocytosis</article-title><source>Traffic</source><year>2013</year><volume>14</volume><fpage>709</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1111/tra.12059</pub-id><?supplied-pmid 23418867?><pub-id pub-id-type="pmid">23418867</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayor</surname><given-names>S</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Donaldson</surname><given-names>JG</given-names></name></person-group><article-title>Clathrin-independent pathways of endocytosis</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2014</year><volume>6</volume><fpage>a016758</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a016758</pub-id><?supplied-pmid 24890511?><pub-id pub-id-type="pmid">24890511</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachse</surname><given-names>M</given-names></name><name><surname>Urb&#x000e9;</surname><given-names>S</given-names></name><name><surname>Oorschot</surname><given-names>V</given-names></name><name><surname>Strous</surname><given-names>GJ</given-names></name><name><surname>Klumperman</surname><given-names>J</given-names></name></person-group><article-title>Bilayered clathrin coats on endosomal vacuoles are involved in protein sorting toward lysosomes</article-title><source>Mol. Biol. Cell</source><year>2002</year><volume>13</volume><fpage>1313</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1091/mbc.01-10-0525</pub-id><?supplied-pmid 11950941?><pub-id pub-id-type="pmid">11950941</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raiborg</surname><given-names>C</given-names></name><name><surname>Wesche</surname><given-names>J</given-names></name><name><surname>Maler&#x000f8;d</surname><given-names>L</given-names></name><name><surname>Stenmark</surname><given-names>H</given-names></name></person-group><article-title>Flat clathrin coats on endosomes mediate degradative protein sorting by scaffolding Hrs in dynamic microdomains</article-title><source>J. Cell Sci.</source><year>2006</year><volume>119</volume><fpage>2414</fpage><lpage>2424</lpage><pub-id pub-id-type="doi">10.1242/jcs.02978</pub-id><?supplied-pmid 16720641?><pub-id pub-id-type="pmid">16720641</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Brain region-specific trafficking of the dopamine transporter</article-title><source>J. Neurosci.</source><year>2015</year><volume>35</volume><fpage>12845</fpage><lpage>12858</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1391-15.2015</pub-id><?supplied-pmid 26377471?><pub-id pub-id-type="pmid">26377471</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nirenberg</surname><given-names>MJ</given-names></name><name><surname>Vaughan</surname><given-names>RA</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name><name><surname>Kuhar</surname><given-names>MJ</given-names></name><name><surname>Pickel</surname><given-names>VM</given-names></name></person-group><article-title>The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons</article-title><source>J. Neurosci.</source><year>1996</year><volume>16</volume><fpage>436</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-02-00436.1996</pub-id><?supplied-pmid 8551328?><pub-id pub-id-type="pmid">8551328</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hersch</surname><given-names>SM</given-names></name><name><surname>Yi</surname><given-names>H</given-names></name><name><surname>Heilman</surname><given-names>CJ</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name></person-group><article-title>Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra</article-title><source>J. Comp. Neurol.</source><year>1997</year><volume>388</volume><fpage>211</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19971117)388:2&#x0003c;211::AID-CNE3&#x0003e;3.0.CO;2-4</pub-id><?supplied-pmid 9368838?><pub-id pub-id-type="pmid">9368838</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>BD</given-names></name><name><surname>Donaldson</surname><given-names>JG</given-names></name></person-group><article-title>Pathways and mechanisms of endocytic recycling</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2009</year><volume>10</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/nrm2755</pub-id><?supplied-pmid 19696797?><pub-id pub-id-type="pmid">19696797</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Saunders, C. et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>97</bold><ext-link ext-link-type="uri" xlink:href="http://www.pnas.org">www.pnas.org</ext-link> (2000).</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>E7138</fpage><lpage>E7147</lpage><pub-id pub-id-type="doi">10.1073/pnas.1511670112</pub-id><?supplied-pmid 26553986?><pub-id pub-id-type="pmid">26553986</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine</article-title><source>Neuropsychopharmacology</source><year>2018</year><volume>43</volume><fpage>2083</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1038/s41386-018-0088-7</pub-id><?supplied-pmid 29795245?><pub-id pub-id-type="pmid">29795245</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlig</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Regulation of dopamine transporter trafficking by intracellular amphetamine</article-title><source>Mol. Pharmacol.</source><year>2006</year><volume>70</volume><fpage>542</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1124/mol.106.023952</pub-id><?supplied-pmid 16684900?><pub-id pub-id-type="pmid">16684900</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Underhill, S. M. <italic>et al</italic>. Amphetamines signal through intracellular TAAR1 receptors coupled to G&#x003b1;13 and G&#x003b1;S in discrete subcellular domains. <italic>Mol. Psychiatry</italic> 1&#x02013;16 (2019), 10.1038/s41380-019-0469-2.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Stamnes</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name></person-group><article-title>Roles of Rho GTPases in intracellular transport and cellular transformation</article-title><source>Int. J. Mol. Sci.</source><year>2013</year><volume>14</volume><fpage>7089</fpage><lpage>7108</lpage><pub-id pub-id-type="doi">10.3390/ijms14047089</pub-id><?supplied-pmid 23538840?><pub-id pub-id-type="pmid">23538840</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinze</surname><given-names>C</given-names></name><name><surname>Boucrot</surname><given-names>E</given-names></name></person-group><article-title>Local actin polymerization during endocytic carrier formation</article-title><source>Biochem. Soc. Trans.</source><year>2018</year><volume>46</volume><fpage>565</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1042/BST20170355</pub-id><?supplied-pmid 29678956?><pub-id pub-id-type="pmid">29678956</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of Piccolo as a regulator of behavioral plasticity and dopamine transporter internalization</article-title><source>Mol. Psychiatry</source><year>2008</year><volume>13</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4002132</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>JD</given-names></name><name><surname>Adkins</surname><given-names>SD</given-names></name><name><surname>Lever</surname><given-names>JR</given-names></name><name><surname>Vaughan</surname><given-names>RA</given-names></name></person-group><article-title>Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol</article-title><source>J. Neurochem.</source><year>2008</year><volume>105</volume><fpage>1683</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05262.x</pub-id><?supplied-pmid 18248623?><pub-id pub-id-type="pmid">18248623</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>WC</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><article-title>Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>32616</fpage><lpage>32626</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.150565</pub-id><?supplied-pmid 20688912?><pub-id pub-id-type="pmid">20688912</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>KT</given-names></name><name><surname>Zhen</surname><given-names>J</given-names></name><name><surname>Reith</surname><given-names>MEA</given-names></name></person-group><article-title>Importance of cholesterol in dopamine transporter function</article-title><source>J. Neurochem.</source><year>2012</year><volume>123</volume><fpage>700</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1111/jnc.12007</pub-id><?supplied-pmid 22957537?><pub-id pub-id-type="pmid">22957537</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adkins</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching</article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>10484</fpage><lpage>10497</lpage><pub-id pub-id-type="doi">10.1021/bi700429z</pub-id><?supplied-pmid 17711354?><pub-id pub-id-type="pmid">17711354</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>A</given-names></name><etal/></person-group><article-title>Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>2874</fpage><lpage>2882</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5345-07.2008</pub-id><?supplied-pmid 18337418?><pub-id pub-id-type="pmid">18337418</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaddii</surname><given-names>M</given-names></name><etal/></person-group><article-title>Flotillin-1/Reggie-2 protein plays dual role in activation of receptor-tyrosine kinase/mitogen-activated protein kinase signaling</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>7265</fpage><lpage>7278</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.287599</pub-id><?supplied-pmid 22232557?><pub-id pub-id-type="pmid">22232557</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname><given-names>PJ</given-names></name><name><surname>Steinberg</surname><given-names>F</given-names></name></person-group><article-title>To degrade or not to degrade: mechanisms and significance of endocytic recycling</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2018</year><volume>19</volume><fpage>679</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0053-7</pub-id><?supplied-pmid 30194414?><pub-id pub-id-type="pmid">30194414</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;neberg</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>IH</given-names></name><name><surname>Iwasa</surname><given-names>JH</given-names></name><name><surname>Hurley</surname><given-names>JH</given-names></name></person-group><article-title>Reverse-topology membrane scission by the ESCRT proteins</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2016</year><volume>18</volume><fpage>5</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.121</pub-id><?supplied-pmid 27703243?><pub-id pub-id-type="pmid">27703243</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifacino</surname><given-names>JS</given-names></name><name><surname>Rojas</surname><given-names>R</given-names></name></person-group><article-title>Retrograde transport from endosomes to the trans-Golgi network</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2006</year><volume>7</volume><fpage>568</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/nrm1985</pub-id><?supplied-pmid 16936697?><pub-id pub-id-type="pmid">16936697</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f6;bius</surname><given-names>W</given-names></name><etal/></person-group><article-title>Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway</article-title><source>Traffic</source><year>2003</year><volume>4</volume><fpage>222</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0854.2003.00072.x</pub-id><?supplied-pmid 12694561?><pub-id pub-id-type="pmid">12694561</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seaman</surname><given-names>MNJ</given-names></name></person-group><article-title>The retromer complex-endosomal protein recycling and beyond</article-title><source>J. Cell Sci.</source><year>2012</year><volume>125</volume><fpage>4693</fpage><lpage>4702</lpage><pub-id pub-id-type="doi">10.1242/jcs.103440</pub-id><?supplied-pmid 23148298?><pub-id pub-id-type="pmid">23148298</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs</article-title><source>J. Neurosci.</source><year>2009</year><volume>29</volume><fpage>6794</fpage><lpage>6808</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4177-08.2009</pub-id><?supplied-pmid 19474307?><pub-id pub-id-type="pmid">19474307</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>J</given-names></name><name><surname>Bj&#x000f8;rn-Yoshimoto</surname><given-names>WE</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>TN</given-names></name><name><surname>Newman</surname><given-names>AH</given-names></name><name><surname>Gether</surname><given-names>U</given-names></name></person-group><article-title>Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>27289</fpage><lpage>27301</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.131003</pub-id><?supplied-pmid 20551317?><pub-id pub-id-type="pmid">20551317</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>WC</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><article-title>Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine-or PKC-regulated endocytosis in dopamine neurons</article-title><source>FASEB J.</source><year>2013</year><volume>27</volume><fpage>2995</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1096/fj.12-218727</pub-id><?supplied-pmid 23612789?><pub-id pub-id-type="pmid">23612789</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>TL</given-names></name><name><surname>Simmons</surname><given-names>D</given-names></name><name><surname>Zahniser</surname><given-names>NR</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Epitope&#x02010;tagged dopamine transporter knock&#x02010;in mice reveal rapid endocytic trafficking and filopodia targeting of the transporter in dopaminergic axons</article-title><source>FASEB J.</source><year>2012</year><volume>26</volume><fpage>1921</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1096/fj.11-196113</pub-id><?supplied-pmid 22267337?><pub-id pub-id-type="pmid">22267337</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Simmons</surname><given-names>D</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Differential subcellular distribution of endosomal compartments and the dopamine transporter in dopaminergic neurons</article-title><source>Mol. Cell. Neurosci.</source><year>2011</year><volume>46</volume><fpage>148</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2010.08.016</pub-id><?supplied-pmid 20816972?><pub-id pub-id-type="pmid">20816972</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>M</given-names></name><name><surname>Dionne</surname><given-names>KR</given-names></name><name><surname>Sorkina</surname><given-names>T</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter</article-title><source>Mol. Biol. Cell</source><year>2007</year><volume>18</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1091/mbc.e06-08-0704</pub-id><?supplied-pmid 17079728?><pub-id pub-id-type="pmid">17079728</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Sorkina</surname><given-names>T</given-names></name><name><surname>Korstjens</surname><given-names>DR</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>35617</fpage><lpage>35624</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506618200</pub-id><?supplied-pmid 16109712?><pub-id pub-id-type="pmid">16109712</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vina-Vilaseca</surname><given-names>A</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><article-title>Lysine 63-linked polyubiquitination of the dopamine transporter requires WW3 and WW4 domains of Nedd4-2 and UBE2D ubiquitin-conjugating enzymes</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>7645</fpage><lpage>7656</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.058990</pub-id><?supplied-pmid 20051513?><pub-id pub-id-type="pmid">20051513</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clague</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Urb&#x000e9;</surname><given-names>S</given-names></name></person-group><article-title>Governance of endocytic trafficking and signaling by reversible ubiquitylation</article-title><source>Dev. Cell</source><year>2012</year><volume>23</volume><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2012.08.011</pub-id><?supplied-pmid 22975321?><pub-id pub-id-type="pmid">22975321</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartier</surname><given-names>E</given-names></name><etal/></person-group><article-title>The SUMO-conjugase Ubc9 prevents the degradation of the dopamine transporter, enhancing its cell surface level and dopamine uptake</article-title><source>Front. Cell. Neurosci.</source><year>2019</year><volume>13</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.3389/fncel.2019.00035</pub-id><?supplied-pmid 30828290?><pub-id pub-id-type="pmid">30828290</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furman</surname><given-names>CA</given-names></name><name><surname>Lo</surname><given-names>CB</given-names></name><name><surname>Stokes</surname><given-names>S</given-names></name><name><surname>Esteban</surname><given-names>JA</given-names></name><name><surname>Gnegy</surname><given-names>ME</given-names></name></person-group><article-title>Rab 11 regulates constitutive dopamine transporter trafficking and function in N2A neuroblastoma cells</article-title><source>Neurosci. Lett.</source><year>2009</year><volume>463</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.07.049</pub-id><?supplied-pmid 19631257?><pub-id pub-id-type="pmid">19631257</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loder</surname><given-names>MK</given-names></name><name><surname>Melikian</surname><given-names>HE</given-names></name></person-group><article-title>The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>22168</fpage><lpage>22174</lpage><pub-id pub-id-type="doi">10.1074/jbc.M301845200</pub-id><?supplied-pmid 12682063?><pub-id pub-id-type="pmid">12682063</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><etal/></person-group><article-title>The dopamine transporter recycles via a retromer-dependent postendocytic mechanism: Tracking studies using a novel fluorophore-coupling approach</article-title><source>J. Neurosci.</source><year>2017</year><volume>37</volume><fpage>9438</fpage><lpage>9452</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3885-16.2017</pub-id><?supplied-pmid 28847807?><pub-id pub-id-type="pmid">28847807</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">Bagalkot, T. R. et al. Dopamine transporter localization in medial forebrain bundle axons indicates its long-range transport primarily by membrane diffusion with a limited contribution of vesicular traffic on retromer-positive compartments. <italic>J. Neurosci</italic>. JN-RM-0744-20 (2020), 10.1523/jneurosci.0744-20.2020.</mixed-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cataldi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice</article-title><source>npj Park. Dis.</source><year>2018</year><volume>4</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41531-018-0063-3</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauffer</surname><given-names>BEL</given-names></name><etal/></person-group><article-title>SNX27 mediates PDZ-directed sorting from endosomes to the plasma membrane</article-title><source>J. Cell Biol.</source><year>2010</year><volume>190</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1083/jcb.201004060</pub-id><?supplied-pmid 20733053?><pub-id pub-id-type="pmid">20733053</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burd</surname><given-names>C</given-names></name><name><surname>Cullen</surname><given-names>PJ</given-names></name></person-group><article-title>Retromer: a master conductor of endosome sorting</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2014</year><volume>6</volume><fpage>a016774</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a016774</pub-id><?supplied-pmid 24492709?><pub-id pub-id-type="pmid">24492709</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="other">Rickhag, M. et al. A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter. <italic>Nat. Commun</italic>. <bold>4</bold>, 1580 (2013).</mixed-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecozzi</surname><given-names>VJ</given-names></name><etal/></person-group><article-title>Pharmacological chaperones stabilize retromer to limit APP processing</article-title><source>Nat. Chem. Biol.</source><year>2014</year><volume>10</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1508</pub-id><?supplied-pmid 24747528?><pub-id pub-id-type="pmid">24747528</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munsie</surname><given-names>LN</given-names></name><etal/></person-group><article-title>Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson&#x02019;s disease VPS35 mutation p.D620N</article-title><source>Hum. Mol. Genet.</source><year>2015</year><volume>24</volume><fpage>1691</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu582</pub-id><?supplied-pmid 25416282?><pub-id pub-id-type="pmid">25416282</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temkin</surname><given-names>P</given-names></name><etal/></person-group><article-title>SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors</article-title><source>Nat. Cell Biol.</source><year>2011</year><volume>13</volume><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1038/ncb2252</pub-id><?supplied-pmid 21602791?><pub-id pub-id-type="pmid">21602791</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>F</given-names></name><etal/></person-group><article-title>A global analysis of SNX27-retromer assembly and cargo specificity reveals a function in glucose and metal ion transport</article-title><source>Nat. Cell Biol.</source><year>2013</year><volume>15</volume><fpage>461</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/ncb2721</pub-id><?supplied-pmid 23563491?><pub-id pub-id-type="pmid">23563491</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clairfeuille</surname><given-names>T</given-names></name><etal/></person-group><article-title>A molecular code for endosomal recycling of phosphorylated cargos by the SNX27-retromer complex</article-title><source>Nat. Struct. Mol. Biol.</source><year>2016</year><volume>23</volume><fpage>921</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3290</pub-id><?supplied-pmid 27595347?><pub-id pub-id-type="pmid">27595347</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Palmitoylation controls recycling in lysosomal sorting and trafficking</article-title><source>Traffic</source><year>2008</year><volume>9</volume><fpage>1984</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00814.x</pub-id><?supplied-pmid 18817523?><pub-id pub-id-type="pmid">18817523</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>JD</given-names></name><name><surname>Vaughan</surname><given-names>RA</given-names></name></person-group><article-title>Palmitoylation controls dopamine transporter kinetics, degradation, and protein kinase C-dependent regulation</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>5175</fpage><lpage>5186</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.187872</pub-id><?supplied-pmid 21118819?><pub-id pub-id-type="pmid">21118819</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastedt</surname><given-names>DE</given-names></name><name><surname>Vaughan</surname><given-names>RA</given-names></name><name><surname>Foster</surname><given-names>JD</given-names></name></person-group><article-title>Palmitoylation mechanisms in dopamine transporter regulation</article-title><source>J. Chem. Neuroanat.</source><year>2017</year><volume>83&#x02013;84</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2017.01.002</pub-id><?supplied-pmid 28115272?><pub-id pub-id-type="pmid">28115272</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Overly</surname><given-names>CC</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name></person-group><article-title>The allen brain atlas: 5 years and beyond</article-title><source>Nat. Rev. Neurosci.</source><year>2009</year><volume>10</volume><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/nrn2722</pub-id><?supplied-pmid 19826436?><pub-id pub-id-type="pmid">19826436</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Cerruti, C., Walther, D. M., Kuhar, M. J. &#x00026; Uhl, G. R. <italic>Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain</italic>. <italic>Molecular Brain Research</italic> vol. 18 (1993).</mixed-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>V</given-names></name><name><surname>Erlmann</surname><given-names>P</given-names></name></person-group><article-title>Protein export at the ER: Loading big collagens into COPII carriers</article-title><source>EMBO J.</source><year>2011</year><volume>30</volume><fpage>3475</fpage><lpage>3480</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.255</pub-id><?supplied-pmid 21878990?><pub-id pub-id-type="pmid">21878990</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucic</surname><given-names>S</given-names></name><etal/></person-group><article-title>The serotonin transporter is an exclusive client of the coat protein complex II (COPII) component SEC24C</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>16482</fpage><lpage>16490</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.230037</pub-id><?supplied-pmid 21454670?><pub-id pub-id-type="pmid">21454670</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Sequence determinants of the Caenhorhabditis elegans dopamine transporter dictating in vivo axonal export and synaptic localization</article-title><source>Mol. Cell. Neurosci.</source><year>2017</year><volume>78</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2016.11.011</pub-id><?supplied-pmid 27913309?><pub-id pub-id-type="pmid">27913309</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><etal/></person-group><article-title>A Triple Arg Motif Mediates &#x003b1; 2B-Adrenergic Receptor Interaction with Sec24C/D and Export</article-title><source>Traffic</source><year>2012</year><volume>13</volume><fpage>857</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2012.01351.x</pub-id><?supplied-pmid 22404651?><pub-id pub-id-type="pmid">22404651</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoze</surname><given-names>N</given-names></name><etal/></person-group><article-title>Heterogeneity of AMPA receptor trafficking and molecular interactions revealed by superresolution analysis of live cell imaging</article-title><source>Proc. Natl Acad. Sci. U. S. A.</source><year>2012</year><volume>109</volume><fpage>17052</fpage><lpage>17057</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204589109</pub-id><?supplied-pmid 23035245?><pub-id pub-id-type="pmid">23035245</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-On</surname><given-names>D</given-names></name><etal/></person-group><article-title>Super-resolution imaging reveals the internal architecture of nano-sized syntaxin clusters</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>27158</fpage><lpage>27167</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.353250</pub-id><?supplied-pmid 22700970?><pub-id pub-id-type="pmid">22700970</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>J</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name></person-group><article-title>Advances in the genetics of Parkinson disease</article-title><source>Nat. Rev. Neurol.</source><year>2013</year><volume>9</volume><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2013.132</pub-id><?supplied-pmid 23857047?><pub-id pub-id-type="pmid">23857047</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human &#x003b1;-synuclein</article-title><source>J. Neurosci. Res.</source><year>2011</year><volume>89</volume><fpage>1091</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1002/jnr.22611</pub-id><?supplied-pmid 21488084?><pub-id pub-id-type="pmid">21488084</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human &#x003b1;-synuclein in mice</article-title><source>Neurobiol. Dis.</source><year>2006</year><volume>21</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.08.005</pub-id><?supplied-pmid 16230020?><pub-id pub-id-type="pmid">16230020</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurz</surname><given-names>A</given-names></name><etal/></person-group><article-title>A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0011464</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuber</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neurodegeneration and motor dysfunction in a conditional model of Parkinson&#x02019;s disease</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>2471</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3040-07.2008</pub-id><?supplied-pmid 18322092?><pub-id pub-id-type="pmid">18322092</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundblad</surname><given-names>M</given-names></name><name><surname>Decressac</surname><given-names>M</given-names></name><name><surname>Mattsson</surname><given-names>B</given-names></name><name><surname>Bj&#x000f6;rklund</surname><given-names>A</given-names></name></person-group><article-title>Impaired neurotransmission caused by overexpression of &#x003b1;-synuclein in nigral dopamine neurons</article-title><source>Proc. Natl Acad. Sci. U. S. A.</source><year>2012</year><volume>109</volume><fpage>3213</fpage><lpage>3219</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200575109</pub-id><?supplied-pmid 22315428?><pub-id pub-id-type="pmid">22315428</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richfield</surname><given-names>EK</given-names></name><etal/></person-group><article-title>Behavioral and neurochemical effects of wild-type and mutated human &#x003b1;-synuclein in transgenic mice</article-title><source>Exp. Neurol.</source><year>2002</year><volume>175</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1006/exnr.2002.7882</pub-id><?supplied-pmid 12009758?><pub-id pub-id-type="pmid">12009758</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wersinger</surname><given-names>C</given-names></name><name><surname>Prou</surname><given-names>D</given-names></name><name><surname>Vernier</surname><given-names>P</given-names></name><name><surname>Niznik</surname><given-names>HB</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Mutations in the lipid-binding domain of &#x003b1;-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity</article-title><source>Mol. Cell. Neurosci.</source><year>2003</year><volume>24</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/S1044-7431(03)00124-6</pub-id><?supplied-pmid 14550771?><pub-id pub-id-type="pmid">14550771</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longhena</surname><given-names>F</given-names></name><name><surname>Faustini</surname><given-names>G</given-names></name><name><surname>Missale</surname><given-names>C</given-names></name><name><surname>Pizzi</surname><given-names>M</given-names></name><name><surname>Bellucci</surname><given-names>A</given-names></name></person-group><article-title>Dopamine transporter/&#x003b1;-synuclein complexes are altered in the post mortem caudate putamen of Parkinson&#x02019;s disease: An in situ proximity ligation assay study</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><fpage>1611</fpage><pub-id pub-id-type="doi">10.3390/ijms19061611</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>B</given-names></name><etal/></person-group><article-title>Dopamine transporter activity is modulated by &#x003b1;-synuclein</article-title><source>J. Biol. Chem.</source><year>2015</year><volume>290</volume><fpage>29542</fpage><lpage>29554</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.691592</pub-id><?supplied-pmid 26442590?><pub-id pub-id-type="pmid">26442590</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swant</surname><given-names>J</given-names></name><etal/></person-group><article-title>&#x00391;-Synuclein Stimulates a Dopamine Transporter-Dependent Chloride Current and Modulates the Activity of the Transporter</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>43933</fpage><lpage>43943</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.241232</pub-id><?supplied-pmid 21990355?><pub-id pub-id-type="pmid">21990355</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wersinger</surname><given-names>C</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Attenuation of dopamine transporter activity by &#x003b1;-synuclein</article-title><source>Neurosci. Lett.</source><year>2003</year><volume>340</volume><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(03)00097-1</pub-id><?supplied-pmid 12672538?><pub-id pub-id-type="pmid">12672538</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wersinger</surname><given-names>C</given-names></name><name><surname>Prou</surname><given-names>D</given-names></name><name><surname>Vernier</surname><given-names>P</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress</article-title><source>FASEB J.</source><year>2003</year><volume>17</volume><fpage>2151</fpage><lpage>2153</lpage><pub-id pub-id-type="doi">10.1096/fj.03-0152fje</pub-id><?supplied-pmid 12958153?><pub-id pub-id-type="pmid">12958153</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wersinger</surname><given-names>C</given-names></name><name><surname>Vernier</surname><given-names>P</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Trypsin Disrupts the Trafficking of the Human Dopamine Transporter by &#x003b1;-Synuclein and Its A30P Mutant</article-title><source>Biochemistry</source><year>2004</year><volume>43</volume><fpage>1242</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1021/bi035308s</pub-id><?supplied-pmid 14756560?><pub-id pub-id-type="pmid">14756560</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JR</given-names></name><etal/></person-group><article-title>PET in LRRK2 mutations: Comparison to sporadic Parkinson&#x02019;s disease and evidence for presymptomatic compensation</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>2777</fpage><lpage>2785</lpage><pub-id pub-id-type="doi">10.1093/brain/awh607</pub-id><?supplied-pmid 16081470?><pub-id pub-id-type="pmid">16081470</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake</article-title><source>Int. J. Biol. Sci.</source><year>2011</year><volume>7</volume><fpage>753</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.7150/ijbs.7.753</pub-id><?supplied-pmid 21698001?><pub-id pub-id-type="pmid">21698001</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Age-dependent dopamine transporter dysfunction and Serine129 phospho-&#x003b1;-synuclein overload in G2019S LRRK2 mice</article-title><source>Acta Neuropathol. Commun.</source><year>2017</year><volume>5</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s40478-017-0426-8</pub-id><?supplied-pmid 28292328?><pub-id pub-id-type="pmid">28292328</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">Volta, M. <italic>et al</italic>. Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. <italic>Elife</italic><bold>6</bold>, (2017).</mixed-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roosen</surname><given-names>DA</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name></person-group><article-title>LRRK2 at the interface of autophagosomes, endosomes and lysosomes</article-title><source>Mol. Neurodegeneration</source><year>2016</year><volume>11</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s13024-016-0140-1</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreij</surname><given-names>AM</given-names></name><etal/></person-group><article-title>LRRK 2 localizes to endosomes and interacts with clathrin&#x02010;light chains to limit Rac1 activation</article-title><source>EMBO Rep.</source><year>2015</year><volume>16</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.15252/embr.201438714</pub-id><?supplied-pmid 25427558?><pub-id pub-id-type="pmid">25427558</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>BMH</given-names></name><etal/></person-group><article-title>A direct interaction between leucine-rich repeat kinase 2 and specific &#x003b2;-Tubulin isoforms regulates tubulin acetylation</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>895</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.507913</pub-id><?supplied-pmid 24275654?><pub-id pub-id-type="pmid">24275654</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><mixed-citation publication-type="other">Godena, V. K. <italic>et al</italic>. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. <italic>Nat. Commun</italic>. <bold>5</bold>, (2014).</mixed-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Suaga</surname><given-names>P</given-names></name><etal/></person-group><article-title>LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity</article-title><source>Hum. Mol. Genet.</source><year>2014</year><volume>23</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu395</pub-id><pub-id pub-id-type="pmid">23933734</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phosphoproteomics reveals that Parkinson&#x02019;s disease kinase LRRK2 regulates a subset of Rab GTPases</article-title><source>Elife</source><year>2016</year><volume>5</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.7554/eLife.12813</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Maio</surname><given-names>R</given-names></name><etal/></person-group><article-title>LRRK2 activation in idiopathic Parkinson&#x02019;s disease</article-title><source>Sci. Transl. Med.</source><year>2018</year><volume>10</volume><fpage>eaar5429</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aar5429</pub-id><?supplied-pmid 30045977?><pub-id pub-id-type="pmid">30045977</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiral</surname><given-names>FR</given-names></name><name><surname>Kohrs</surname><given-names>FE</given-names></name><name><surname>Jin</surname><given-names>EJ</given-names></name><name><surname>Hiesinger</surname><given-names>PR</given-names></name></person-group><article-title>Rab GTPases and Membrane Trafficking in Neurodegeneration</article-title><source>Curr. Biol.</source><year>2018</year><volume>28</volume><fpage>R471</fpage><lpage>R486</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2018.02.010</pub-id><?supplied-pmid 29689231?><pub-id pub-id-type="pmid">29689231</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>BL</given-names></name></person-group><article-title>Rabs, Membrane Dynamics, and Parkinson&#x02019;s Disease</article-title><source>J. Cell. Physiol.</source><year>2017</year><volume>232</volume><fpage>1626</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.1002/jcp.25713</pub-id><?supplied-pmid 27925204?><pub-id pub-id-type="pmid">27925204</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>RM</given-names></name><etal/></person-group><article-title>LRRK2 phosphorylates novel tau epitopes and promotes tauopathy</article-title><source>Acta Neuropathol.</source><year>2013</year><volume>126</volume><fpage>809</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1188-4</pub-id><?supplied-pmid 24113872?><pub-id pub-id-type="pmid">24113872</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melrose</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice</article-title><source>Neurobiol. Dis.</source><year>2010</year><volume>40</volume><fpage>503</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2010.07.010</pub-id><?supplied-pmid 20659558?><pub-id pub-id-type="pmid">20659558</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><mixed-citation publication-type="other">Lucas, R. M. <italic>et al</italic>. LRRK2-mediated phosphorylation of HDAC6 regulates HDAC6-cytoplasmic dynein interaction and aggresome formation. <italic>bioRxiv</italic> 554881 (2019), 10.1101/554881.</mixed-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilari&#x000f1;o-G&#x000fc;ell</surname><given-names>C</given-names></name><etal/></person-group><article-title>VPS35 mutations in parkinson disease</article-title><source>Am. J. Hum. Genet.</source><year>2011</year><volume>89</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.001</pub-id><?supplied-pmid 21763482?><pub-id pub-id-type="pmid">21763482</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimprich</surname><given-names>A</given-names></name><etal/></person-group><article-title>A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset parkinson disease</article-title><source>Am. J. Hum. Genet.</source><year>2011</year><volume>89</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.008</pub-id><?supplied-pmid 21763483?><pub-id pub-id-type="pmid">21763483</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavodszky</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mutation in VPS35 associated with Parkinson&#x02019;s disease impairs WASH complex association and inhibits autophagy</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3828</fpage><pub-id pub-id-type="doi">10.1038/ncomms4828</pub-id><?supplied-pmid 24819384?><pub-id pub-id-type="pmid">24819384</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><mixed-citation publication-type="other">Huang, Y. <italic>et al</italic>. VPS35 Interacts with Dopamine Transportor and Disrupts Dopamine Transporter Recycling Pathway. <italic>SSRN Electron. J</italic>. (2020), 10.2139/ssrn.3315811.</mixed-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puthenveedu</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Sequence-dependent sorting of recycling proteins by actin-stabilized endosomal microdomains</article-title><source>Cell</source><year>2010</year><volume>143</volume><fpage>761</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.10.003</pub-id><?supplied-pmid 21111236?><pub-id pub-id-type="pmid">21111236</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><mixed-citation publication-type="other">Lee, S., Chang, J. &#x00026; Blackstone, C. FAM21 directs SNX27-retromer cargoes to the plasma membrane by preventing transport to the Golgi apparatus. <italic>Nat. Commun</italic>. <bold>7</bold>, (2016).</mixed-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoshita</surname><given-names>T</given-names></name><etal/></person-group><article-title>Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>2933</fpage><lpage>2948</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx179</pub-id><?supplied-pmid 28482024?><pub-id pub-id-type="pmid">28482024</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mir</surname><given-names>R</given-names></name><etal/></person-group><article-title>The Parkinson&#x02019;s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human</article-title><source>Biochem. J.</source><year>2018</year><volume>475</volume><fpage>1861</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1042/BCJ20180248</pub-id><?supplied-pmid 29743203?><pub-id pub-id-type="pmid">29743203</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLeod</surname><given-names>DA</given-names></name><etal/></person-group><article-title>RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson&#x02019;s Disease Risk</article-title><source>Neuron</source><year>2013</year><volume>77</volume><fpage>425</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.11.033</pub-id><?supplied-pmid 23395371?><pub-id pub-id-type="pmid">23395371</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><article-title>How does parkin ligate ubiquitin to Parkinson&#x02019;s disease? First in molecular medicine review series</article-title><source>EMBO Rep.</source><year>2004</year><volume>5</volume><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400188</pub-id><?supplied-pmid 15229644?><pub-id pub-id-type="pmid">15229644</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;cking</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Association between Early-Onset Parkinson&#x02019;s Disease and Mutations in the Parkin Gene</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>1560</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005253422103</pub-id><?supplied-pmid 10824074?><pub-id pub-id-type="pmid">10824074</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><mixed-citation publication-type="other">Isaacs, D., Claassen, D., Bowman, A. B. &#x00026; Hedera, P. Phenotypic discordance in siblings with identical compound heterozygous PARK2 mutations. <italic>Brain Sci</italic>. <bold>7</bold>, (2017).</mixed-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varrone</surname><given-names>A</given-names></name><etal/></person-group><article-title>Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>2097</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000145765.19094.94</pub-id><?supplied-pmid 15596756?><pub-id pub-id-type="pmid">15596756</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moszczynska</surname><given-names>A</given-names></name><etal/></person-group><article-title>Parkin disrupts the &#x003b1;-synuclein/dopamine transporter interaction: Consequences toward dopamine-induced toxicity</article-title><source>J. Mol. Neurosci.</source><year>2007</year><volume>32</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1007/s12031-007-0037-0</pub-id><?supplied-pmid 17873367?><pub-id pub-id-type="pmid">17873367</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Trajkovic</surname><given-names>K</given-names></name><name><surname>Tsunemi</surname><given-names>T</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name></person-group><article-title>Parkin modulates endosomal organization and function of the endo-lysosomal pathway</article-title><source>J. Neurosci.</source><year>2016</year><volume>36</volume><fpage>2425</fpage><lpage>2437</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2569-15.2016</pub-id><?supplied-pmid 26911690?><pub-id pub-id-type="pmid">26911690</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting</article-title><source>Hum. Mol. Genet.</source><year>2018</year><volume>27</volume><fpage>3189</fpage><lpage>3205</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy224</pub-id><?supplied-pmid 29893854?><pub-id pub-id-type="pmid">29893854</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallon</surname><given-names>L</given-names></name><etal/></person-group><article-title>A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling</article-title><source>Nat. Cell Biol.</source><year>2006</year><volume>8</volume><fpage>834</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1038/ncb1441</pub-id><?supplied-pmid 16862145?><pub-id pub-id-type="pmid">16862145</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itier</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse</article-title><source>Hum. Mol. Genet.</source><year>2003</year><volume>12</volume><fpage>2277</fpage><lpage>2291</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg239</pub-id><?supplied-pmid 12915482?><pub-id pub-id-type="pmid">12915482</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>G</given-names></name><etal/></person-group><article-title>Impaired in vivo dopamine release in parkin knockout mice</article-title><source>Brain Res.</source><year>2010</year><volume>1352</volume><fpage>214</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2010.06.065</pub-id><?supplied-pmid 20620130?><pub-id pub-id-type="pmid">20620130</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells</article-title><source>Nat. Commun.</source><year>2012</year><volume>3</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ncomms1669</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JY</given-names></name><etal/></person-group><article-title>The RIT2 and STX1B polymorphisms are associated with Parkinson&#x02019;s disease</article-title><source>Park. Relat. Disord.</source><year>2015</year><volume>21</volume><fpage>300</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.12.006</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emamalizadeh</surname><given-names>B</given-names></name><etal/></person-group><article-title>RIT2, a susceptibility gene for Parkinson&#x02019;s disease in Iranian population</article-title><source>Neurobiol. Aging</source><year>2014</year><volume>35</volume><fpage>e27</fpage><lpage>e28</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.07.013</pub-id><?supplied-pmid 25146456?><pub-id pub-id-type="pmid">25146456</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><mixed-citation publication-type="other">Lu, Y. et al. Genetic association of RIT2 rs12456492 polymorphism and Parkinson&#x02019;s disease susceptibility in Asian populations: a meta-analysis. <italic>Sci. Rep</italic>. <bold>5</bold>, 13805 (2015).</mixed-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Genetic association study between RIT2 and Parkinson&#x02019;s disease in a Han Chinese population</article-title><source>Neurol. Sci.</source><year>2017</year><volume>38</volume><fpage>343</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1007/s10072-016-2784-6</pub-id><?supplied-pmid 27889863?><pub-id pub-id-type="pmid">27889863</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossers</surname><given-names>K</given-names></name><etal/></person-group><article-title>Analysis of gene expression in Parkinson&#x02019;s disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death</article-title><source>Brain Pathol.</source><year>2009</year><volume>19</volume><fpage>91</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00171.x</pub-id><?supplied-pmid 18462474?><pub-id pub-id-type="pmid">18462474</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Conditional, inducible gene silencing in dopamine neurons reveals a sex-specific role for Rit2 GTPase in acute cocaine response and striatal function</article-title><source>Neuropsychopharmacology</source><year>2020</year><volume>45</volume><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41386-019-0457-x</pub-id><?supplied-pmid 31277075?><pub-id pub-id-type="pmid">31277075</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>QD</given-names></name><name><surname>Rooney</surname><given-names>MB</given-names></name><name><surname>Wightman</surname><given-names>RM</given-names></name><name><surname>Kuhn</surname><given-names>CM</given-names></name></person-group><article-title>Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry</article-title><source>Neuroscience</source><year>1999</year><volume>95</volume><fpage>1061</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(99)00500-X</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>TL</given-names></name></person-group><article-title>Attenuation of dopamine uptake in vivo following priming with estradiol benzoate</article-title><source>Brain Res.</source><year>1999</year><volume>834</volume><fpage>164</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(99)01508-5</pub-id><?supplied-pmid 10407108?><pub-id pub-id-type="pmid">10407108</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boss&#x000e9;</surname><given-names>R</given-names></name><name><surname>Rivest</surname><given-names>R</given-names></name><name><surname>Di Paolo</surname><given-names>T</given-names></name></person-group><article-title>Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain</article-title><source>Mol. Brain Res.</source><year>1997</year><volume>46</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/S0169-328X(97)00082-X</pub-id><?supplied-pmid 9191114?><pub-id pub-id-type="pmid">9191114</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Disshon</surname><given-names>KA</given-names></name><name><surname>Boja</surname><given-names>JW</given-names></name><name><surname>Dluzen</surname><given-names>DE</given-names></name></person-group><article-title>Inhibition of striatal dopamine transporter activity by 17&#x003b2;-estradiol</article-title><source>Eur. J. Pharmacol.</source><year>1998</year><volume>345</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(98)00008-9</pub-id><?supplied-pmid 9600639?><pub-id pub-id-type="pmid">9600639</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>QD</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Kuhn</surname><given-names>CM</given-names></name></person-group><article-title>Sex differences in neurochemical effects of dopaminergic drugs in rat striatum</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>1193</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300915</pub-id><?supplied-pmid 16237396?><pub-id pub-id-type="pmid">16237396</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>GE</given-names></name><name><surname>Pienaar</surname><given-names>IS</given-names></name><name><surname>Vohra</surname><given-names>S</given-names></name><name><surname>Qamhawi</surname><given-names>Z</given-names></name></person-group><article-title>Sex differences in Parkinson&#x02019;s disease</article-title><source>Front. Neuroendocrinol.</source><year>2014</year><volume>35</volume><fpage>370</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2014.02.002</pub-id><?supplied-pmid 24607323?><pub-id pub-id-type="pmid">24607323</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulzer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>11869</fpage><lpage>11874</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.22.11869</pub-id><?supplied-pmid 11050221?><pub-id pub-id-type="pmid">11050221</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoud</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits</article-title><source>Neurobiol. Dis.</source><year>2015</year><volume>74</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.10.016</pub-id><?supplied-pmid 25447236?><pub-id pub-id-type="pmid">25447236</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filloux</surname><given-names>F</given-names></name><name><surname>Townsend</surname><given-names>JJ</given-names></name></person-group><article-title>Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection</article-title><source>Exp. Neurol.</source><year>1993</year><volume>119</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1006/exnr.1993.1008</pub-id><?supplied-pmid 8432353?><pub-id pub-id-type="pmid">8432353</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson&#x02019;s Disease Mutation G2019S</article-title><source>J. Neurosci</source><year>2010</year><volume>30</volume><fpage>1788</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5604-09.2010</pub-id><?supplied-pmid 20130188?><pub-id pub-id-type="pmid">20130188</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanping</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson&#x02019;s disease</article-title><source>Nat. Neurosci</source><year>2009</year><volume>12</volume><fpage>826</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/nn.2349</pub-id><pub-id pub-id-type="pmid">19503083</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramonet</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e18568</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0018568</pub-id><?supplied-pmid 21494637?><pub-id pub-id-type="pmid">21494637</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice</article-title><source>Proc. Natl Acad. Sci</source><year>2009</year><volume>106</volume><fpage>14622</fpage><lpage>14627</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906334106</pub-id><?supplied-pmid 19667187?><pub-id pub-id-type="pmid">19667187</pub-id></element-citation></ref></ref-list></back></article>